Post Operative Troponin-T level as a marker of Extent of myocardial ischemic injury in mitral Valve replacement surgeries by Jothilingam, N
Dissertation on 
POST-OPERATIVE TROPONIN-T LEVEL AS A MARKER OF 
EXTENT OF MYOCARDIAL ISCHEMIC INJURY IN MITRAL 
VALVE REPLACEMENT SURGERIES 
Submitted in partial fulfillment of requirements of 
M.Ch DEGREE EXAMINATION 
BRANCH I 
CARDIOVASCULAR AND THORACIC SURGERY 
August 2013 
Madras Medical College and Rajiv Gandhi Government General 
Hospital, 
Chennai-600003 
  
 
 
 
CERTIFICATE 
This is to certify that the dissertation entitled “POST-OPERATIVE TROPONIN-T 
LEVEL AS A MARKER OF EXTENT OF MYOCARDIAL ISCHEMIC INJURY IN 
MITRAL VALVE REPLACEMENT SURGERIES” presented here is the original work 
done by DR.JOTHILINGAM.N in the department of Cardiothoracic Surgery, Rajiv 
Gandhi Government General Hospital, Medical College, Chennai-600003, in partial 
fulfillment of the University Rules and Regulations for the award of Branch I M.Ch 
Cardiovascular and Thoracic Surgery degree under our guidance and supervision during the 
academic period from 2010-2013. 
 
Prof.DR.V.KANAGASABAI,M.D.,  Prof.DR.S.MANOHARAN,M.Ch., 
THE DEAN,      PROFESSOR AND HOD, 
Madras Medical College,     Department of Cardiovascular and  
Rajiv Gandhi General Hospital,   Thoracic Surgery, 
Chennai-600003     MMC/RGGGH, Chennai-600003 
 
 
 
 
 
 
 
 
 
DECLARATION 
I, Dr. N. JOTHILINGAM, hereby solemnly declare that this dissertation titled 
“POSTOPERATIVE TROPONIN-T LEVEL AS A MARKER OF EXTENT OF 
MYOCARDIAL ISCHEMIC INJURY IN MITRAL VALVE REPLACEMENT 
SURGERIES” was done by me in the department of Cardiothoracic surgery, Madras 
Medical College and Rajiv Gandhi Government General Hospital, Chennai-600003 
during the period from March 2012 to March  2013 under the guidance and 
supervision of Prof. Dr. T.S.Manoharan,MS,MCh,. This dissertation is submitted to 
the Tamilnadu Dr.  M. G. R. Medical University towards the partial fulfillment of 
requirement for the award of  M.Ch.  Degree in Cardiothoracic Surgery. 
 
 
Date  :       Signature of the candidate 
Place : 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
I thank Prof.Dr.Kanakasabai, and Ethical Committee for approving this study to be 
performed in Rajiv Gandhi Government General Hospital & Madras Medical College, 
Chennai-600003. 
I sincerely thank Prof.Dr.T.S.Manoharan, for allowing me to conduct this study in 
our hospital and also for his valuable guidance in formatting the study design. 
I thank Prof.Dr.K.Raja Venkatesh, for his immense help during the course of study, 
by teaching valuable clinical points. 
I thank Prof.Dr.R.K.Sasankh, Prof.Dr.N.Nagarajan, Prof.Dr.Ganesan, 
Prof.Dr.B.Mariappan, and Dr.Kasinathan for their guidance as well as for providing me 
enough time for preparation of this dissertation. 
I also thank formerly (Retired) Prof.Dr.Sundaram, Prof.Dr.P.Moorthy, 
Prof.Dr.Ponnusamy for their invaluable support during the study. 
I humbly lay my thanks to (late) Prof.Dr.Varadharajulu, for his extreme moral 
support during my earlier days in MCh course. 
I thank Dr.Sivaraman, Dr.Amirtharaj, Dr.Shivanraj, Dr.Arunkumar, Dr.Prasanna, 
Dr.Dinesh for their unintentional kind help and for teaching me the basics and surgical 
techniques of cardiothoracic surgery. 
I thank all the anesthetists who were very helpful in completing the study. 
I thank all the staff nurses and other health workers in our hospital for their help and 
co-operation during my course. 
I thank Dr.Kumaresan Kuppusamy, for his important and valuable guidance in 
statistical analysis of this study. 
Lastly, but more importantly and sincerely, I thank all my patients who happily 
volunteered for participating in this study and, for being the whole reason why new 
developments in surgical field are possible, by providing unconditional submission of their 
own health status for such studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INDEX 
 
TITLES         PAGE NO. 
Introduction and Aim of study 
Review of Literature 
Materials and Methods 
Results 
Discussion 
Conclusion 
Bibliography 
 
 
 
ANNEXURES 
Master chart 
Ethical Committee Approval Form 
Patient consent form 
Plagiarism (Turnitin) Receipt 
 
 
 
 
  
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
MATERIALS AND METHODS 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
RESULTS 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
DISCUSSION 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
CONCLUSION 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
BIBLIOGRAPHY 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
ANNEXURES 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
1 
 
INTRODUCTION 
 Cardiac surgery is often complicated by some degree of myocardial ischemic 
damage, despite much improvement in myocardial protection strategies and surgical 
techniques. But, precise markers that can easily and specifically identify and quantify the 
extent of such damage is lacking. Electrocardiographic changes are of limited value in the 
perioperative period. Trans-esophageal echocardiography may be helpful in assessing left 
ventricular function and regional wall motion (which are indirect indicators of adequacy of 
myocardial protection) but it lacks the sensitivity to detect subtle degrees of myocardial 
damage. But, it is very essential to identify perioperative myocardial injury and its extent 
because it directly affects postoperative outcome. Further, the assessment of such injury is 
helpful to compare different methods of myocardial protection and will be useful in 
perioperative management of patients. 
 The development and availability of Troponin assays are considered to be one of the 
most important innovations in the past decade in cardiac diagnostics. Cardiac troponins 
(Troponin-T and Troponin-I) are proteins that are present in the thin filaments of myofibrils. 
They are released into the circulation whenever there is myocardial damage. Cardiac 
troponins are specific for cardiac muscle and are not expressed in skeletal muscle fibers. 
Due to their high sensitivity and specificity, they are appropriate markers for perioperative 
myocardial ischemic injury. 
 But several studies, which have plotted the kinetics of the Troponins, have shown 
that cardiac surgery per se, causes elevation of Troponin levels in the blood even when 
there is no evidence of myocardial ischemic damage. This is because of surgical trauma to 
the myocardium. The level of increase varies with different types of surgeries and with 
different lengths of incisions. It is difficult to define a cut-off value for Troponin levels 
which will indicate a perioperative MI in patients who have undergone CABG, because 
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Troponin is universally elevated in all patients who undergo cardiac surgery. This rise is 
due to both surgical trauma and myocardial ischemic injury. Thus, the significance of 
Troponin levels in post-cardiac surgery patients is still ill-defined. 
 However, we hypothesized that if high Troponin levels result in poor postoperative 
outcomes (e.g. increased duration of ventilation, duration of ICU stay, duration of inotropic 
requirement, cardiac failure, mortality, etc.) and vice versa, that would indicate that 
Troponin is a reliable marker for extent of myocardial “ischemic” damage because pure 
surgical trauma alone (which is same for any single type of surgery) is not going to have 
any influence on these postoperative outcomes. 
 
AIM OF THE STUDY 
Our prospective study was thus designed to analyse the correlation between 
postoperative outcomes and Troponin-T level and to find out if there is any positive 
correlation between Aortic cross clamp time and Troponin-T.  
If there is definite positive correlation between aortic cross clamp time and 
Troponin-T levels and between postoperative outcomes and Troponin-T levels, that 
becomes a definite evidence that this test is a viable and effective test in cardiac surgical 
field to assess the extent of myocardial ischemic injury. 
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REVIEW OF LITERATURE 
HISTORY OF EVOLUTION OF THE CONCEPT OF MYOCARDIAL 
PROTECTION 
Cardiac surgical procedures have been considered as unrealistic attempts even just 
100 years back. Billroth and Paget have viewed cardiac surgery with skepticism.  The first 
successful cardiac surgical procedure was the suturing of a stab wound in the right ventricle 
by Ludwig van Rehn in 1986. In 1902, Luther Hill performed a successful surgical 
procedure for a case of cardiac tamponade. These procedures, seemingly simple now, were 
performed one hundred years back as emergency resuscitative measures when cardiac 
surgery was unknown. 
Frederick Trendelenburg performed experimental pulmonary embolectomy in 
animals using “inflow occlusion” technique. Kirschner, a student of Trendelenburg, 
performed a successful pulmonary embolectomy in a human in 1924 using the same inflow 
occlusion technique. The need for myocardial protection was not known at that time. The 
inflow occlusion was used just to get a bloodless field. 
Alexis Carrel performed a descending aorta to coronary artery anastomosis in 1910 
in a dog. He was able to finish this anastomosis within 3 minutes of interruption of 
circulation. But, the fact that the heart fibrillated within these 3 minutes and the dog 
subsequently died after 2 hours, made him conclude that the anastomosis should be 
completed within 3 minutes and this important observation led to the knowledge that the 
heart cannot withstand ischemia under fibrillating conditions. 
Gibbon developed a cardiopulmonary bypass machine and started doing surgeries 
for congenital heart diseases in children. Due to repeated failures, he subsequently stopped 
using the machine. 
4 
 
Lillehei, using cross circulation, proved that heart surgeries could be feasible. CPB 
technology helped him perform successful surgeries and hence abandoned cross circulation 
after using it in 45 patients from 1954 to 1955.  
During the next few decades, the concept of global organ protection evolved with 
the use of hypothermia. In 1961, Hufnagel and colleagues introduced the concept of 
myocardial cooling by ice slush.  
Gradually, more complex cardiac surgeries were attempted. These procedures 
obviously needed longer periods of ischemia. Hence all these hearts suffered greater 
ischemic damage which was a great concern. Hypothermia was used to protect the heart 
from severe ischemic injury by lowering basal metabolic rate. But it did not provide a 
satisfactory protection for the heart. The concept of aortic cross-clamping was then applied. 
The heart stopped beating because of deprivation of high energy phosphate stores due to 
absence of blood supply. The cross-clamping technique greatly facilitated the surgery but at 
the same time making the heart prone to greater ischemic injury. 
At this time, Melrose described that the heart could be arrested by chemical 
technique rather than by ischemic technique. He used potassium citrate to chemically arrest 
the heart and postulated that this preserves high energy phosphates in the heart and hence it 
is safe. But contrary to his expectations, this technique did not provide adequate myocardial 
protection and was in fact abandoned in many centers. Topical hypothermia was then added 
as an adjunct to this form of cardioplegia for better cardiac protection. In St. Thomas 
Hospital in London, Hearse et al. developed a solution, which provided reliable cardiac 
arrest and good myocardial protection.1 
Gay and Ebert refined cardioplegia formulations in 1970s and 1980s. Follett and 
Buckberg described various strategies of cardioplegia delivery (temperature of cardioplegia 
solution, various routes of administration, etc). Buckberg found that blood was very useful 
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as a medium for cardioplegia administration. The composition of cardioplegic solutions 
continue to be modified worldwide according to various study reports proving superiority of 
one over another. 
 In 1978, Buckberg showed the importance of use of hyperkalemic reperfusate 
initially before aortic cross clamp is released.2        
DAMAGE FROM MYOCARDIAL ISCHEMIA 
Functional impairment of cardiac muscle in the absence of muscle necrosis is called 
myocardial stunning. This is usually a reversible phenomenon though it may last for few 
minutes to few days. 
Myocardial cell necrosis occurs when the ischemic process is prolonged though the 
time duration beyond which necrosis of muscle fibers starts has not yet been defined. The 
extent of myocardial cell necrosis is strongly influenced by various myocardial protection 
strategies. 
Contracture develops in cardiac muscle when ATP levels become critically low. 
This phenomenon is demonstrable in animals but uncommon in humans probably because 
the time to contracture is quite long in humans. The stone heart phenomenon usually starts 
in basal region of left ventricle and in subendocardium. 
DAMAGE FROM REPERFUSION 
Reperfusion damage to the myocardium is due to uncontrolled reperfusion i.e. 
reperfusion by unmodified blood and without control of flow or pressure.2 
The mechanism of reperfusion injury involves free oxygen radicals and calcium 
influx into myocytes.  
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The event of myocardial damage sustained due to ischemia cannot be separated from 
that due to reperfusion injury because both are interdependent. But the surgeon has the 
unique opportunity to control these two events separately. 
As the duration of ischemia prolongs, the myocardium undergoes the stage of 
myocardial stunning initially, and then myocardial necrosis. If ischemic process continues, 
stone heart develops, which usually indicates irreversible myocardial damage. This same 
course of events apply to reperfusion injury also. 
In any one heart, different areas of myocardium may be different stages of ischemic 
injury. Usually patchy areas of necrosis are interspersed among normal areas of viable 
myocardium. 
Microscopically, both apoptosis (programmed cell death without inflammation) and 
cell necrosis (cell death associated with inflammation) occur in post-cardiac surgical 
patients. Markus Malmberg, has demonstrated in animal studies that more the cardiac 
ischemic time more the degree apoptosis in cardiac muscle and also that ischemic 
preconditioning reduces the degree of apoptosis for any given duration of ischemic time. 
 
VULNERABILITY OF THE DISEASED HEART 
 Hypertrophied heart is more susceptible to ischemic and reperfusion injury than a 
normal sized heart. 
Chronic heart failure makes the heart more vulnerable to ischemic damage due to its 
already energy depleted state.  
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SURGICAL REQUIREMENTS 
Cardiac operations can be performed when the heart is beating and it is being 
perfused or during induced ventricular fibrillation, but a precise and complete intracardiac 
surgical procedure requires a quiescent heart and a bloodless field. This would also prevent 
systemic air embolism. Hence aortic cross clamping becomes a necessity for most cardiac 
operations. So, myocardial protection becomes mandatory in order to prevent ischemic 
myocardial damage. Cardiac activity should be immediately stopped to prevent depletion of 
high energy phosphate stores. This is accomplished by chemical cardiac arrest by 
cardioplegic solution containing potassium. 
  Since aortic cross clamping and cardioplegic arrest of the heart are routine 
procedures in open heart surgeries and during aortic cross clamping the heart is deprived of 
its blood supply through coronaries, various standardized myocardial strategies have 
evolved over time to avoid ischemic damage to the myocardium during this period of 
myocardial ischemia.  Some of them are projected to be superior to other techniques by 
various studies. But cardioplegic arrest of the heart is the gold standard against which others 
may be compared. 
CARDIOPLEGIA DELIVERY METHODS 
The goal of any technique of cardioplegia administration is to have uniform 
distribution of the solution to entire myocardium thus ensuring good myocardial protection. 
However, there is no single technique that is “best” for all circumstances. A practical 
knowledge of all the available techniques will help in special situations where other modes 
of cardioplegia delivery will be more useful than the conventional one in providing 
optimum protection to the myocardium. 
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Antegrade cardioplegia: 
In this technique, the cardioplegia is administered through aortic root, coronary ostia 
or bypass conduits after completing distal anastomosis in CABG. 
Most of the centers worldwide use the antegrade technique where cardioplegia is 
infused through aortic root because the technique is simple and efficient. It mimics the 
natural way of blood flow through coronaries. This method is not suitable in cases of aortic 
regurgitation or dissection in which aortotomy is done and the solution is administered 
through coronary ostia. Lifting or retraction of the heart (e.g. in Mitral valve surgeries) 
distorts the aortic valve and hence the heart must be repositioned before administering 
cardioplegia through aortic root. 
Intermittent and continuous cardioplegia: 
Continuous cardioplegia provides better myocardial protection but it is difficult to 
have a bloodless field in this technique and it also complicates the surgical field due to 
additional cannulae. 
Retrograde cardioplegia: 
It is helpful in patients with significant coronary artery stenoses where antegrade 
cardioplegia alone may not result in adequate distribution to entire myocardium. In this 
method, cardioplegia can be administered without interrupting the conduct of surgery. It is 
also useful for de-airing the coronaries and aortic root. 
The right ventricle and posterior aspects of the septum are not adequately perfused 
by cardioplegic solution in this method due to proximity of their draining veins to the 
coronary sinus ostium. 
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It is also important to limit the retrograde pressure from 25 to 35 mmHg. Pressures 
of more than 50 mmHg will produce myocardial edema and hemorrhage. 
Combined antegrade and retrograde cardioplegia: 
This method provides the opportunity to gain optimum benefits of both antegrade 
and retrograde cardioplegias in a single patient. 
Various compositions of cardioplegia solutions: 
Basically two different types of solutions are described: 
1. Extracellular or St. Thomas solution type 
2. Intracellular or Breschneider solution type. 
Extracellular solutions contain high sodium and calcium content with added magnesium. 
Intracellular solutions contain low sodium and calcium concentrations. Of these two types, 
the extracellular type is the most commonly used cardioplegia solution worldwide though 
some centers still continue to use intracellular type. 
Each of these subtypes has been modified in their compositions and concentrations by 
different manufacturers. 
Crystalloid and blood cardioplegia: 
Crystalloid cardioplegia is simple, cheap and easy to prepare and administer. Blood 
cardioplegia provides the following benefits: 
1. Ability to carry oxygen 
2. Excellent buffering capacity 
3. Scavenges free oxygen radicals 
4. Electrolyte and osmotic compositions are similar to blood 
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Temperature of cardioplegia solution: 
Cold cardioplegia (administered at 4 degree Celsius) is believed to provide better 
myocardial protection than warm cardioplegia (administered at 34-35 degree Celsius) 
though some studies have proved both of them to be equally effective. Tepid cardioplegia 
(28 degree Celcius) may provide advantages of both cold and warm solutions. 
 Additives in cardioplegia: 
Since the potassium used in the cardioplegia is injurious to coronary vascular 
endothelium, additives are being tried which may reduce the dose of potassium to produce 
cardiac arrest. 
 Nicorandil, an ATP sensitive potassium channel opener, is one such agent used to 
reduce the dose of potassium in cardioplegia solution. This drug also prevents perioperative 
coronary spasm. It has also been proved to precondition the heart against subsequent 
ischemic injury. 
L-arginine acts as a nitric oxide donor and helps in preventing endothelial 
dysfunction in ischemia-reperfusion injury. Its addition in cardioplegia solution has been 
shown to reduce postoperative Troponin-T release.1 
ADDITIONAL STRATEGIES OF MYOCARDIAL PROTECTION: 
Volatile anesthetic agents: 
Volatile anesthetic agents (Isoflurane, Sevoflurane) have been proved to enhance 
myocardial protection by poorly understood complex and multifactorial mechanisms. They 
ameliorate the deleterious effects of free oxygen radicals in the phase of ischemia-
reperfusion. In addition, they modulate potassium dependent ATP channels and produces 
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preconditioning effect. It has been shown that postoperative Troponin-T release is reduced 
with their use in anesthesia. Postoperative left ventricular function also is improved. 
 
Acute Normovolemic Hemodilution (ANH): 
This technique helps in better myocardial protection in two ways. First, it reduces 
requirement of blood transfusion. Secondly, it improves the rheologic characteristics of the 
blood and a reduction in hematocrit results in lower viscosity. This enhances myocardial 
blood flow to underserved areas of the myocardium.  
Neutrophil depletion: 
Neutrophils are associated with reperfusion injury by its release of destructive 
enzymes, free oxygen radicals and other toxic substances. Neutrophil depletion, either in 
CPB circuit or in cardioplegia solution has been shown to improve postoperative 
myocardial performance. Postoperative Troponin-T is also less in these patients. 
Other medications useful in myocardial protection: 
Erythropoietin, N-acetylcysteine, Desferoxamine and Statins have also been proved 
to enhance myocardial protection in some studies.1 
ISCHEMIC PRECONDITIONING: 
It is a phenomenon in which a previous sublethal ischemia to the myocardium 
provides protection against subsequent ischemic insults. In a study conducted by Ghosh et 
al. postoperative release of Troponin-T was less in those patients in whom ischemic 
preconditioning was applied. 
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FIBRILLATION: 
It is a useful, but less often used, strategy for myocardial protection. It relies on the 
principle of ischemic preconditioning. It is particularly useful in reoperative CABG 
surgeries where dissection and isolation of previous grafts and delivery of cardioplegia 
through them is difficult. 
WHAT IS TROPONIN-T: 
Troponin-T was discovered by Hugo A. Katus, a German physician. He 
subsequently developed a method to assay Troponin-T level. 
The cardiac muscle is made up of myocyte composed of bundles of myofibrils 
which contain myofilaments. These myofibrils in turn are made up of repeating units of 
sarcomere. These sarcomeres are the basic contractile units of cardiac muscle. Each 
sarcomere is defined on either side by z lines. The sarcomere contains actin (thin filament) 
and myosin (thick filament). The interaction between actin and myosin and their sliding of 
one over another causes contraction and relaxation of cardiac muscle. Myosin has ATPase 
that hydrolyses ATP to provide energy for actin-myosin bridge formation. Thin filament is 
made up of three types of proteins:  actin, troponin and tropomyosin. Actin is globular 
shaped protein arranged around rod shaped tropomyosin. Troponin proteins are attached to 
tropomyosin at regular intervals. 3 types of troponin proteins: Troponin-T, Troponin-C& 
Troponin-I (each coded by a separate gene). Troponin-T is attached to tropomyosin and 
troponin-C (which in turn is attached to Troponin-T) is the site for Calcium binding. During 
excitation-contraction coupling, calcium channels on sarcoplasmic reticulum open and 
calcium is released into sarcoplasm. These calcium ions bind to Troponin-C and bring about 
conformational changes in Troponin-T causing actin-myosin overlap. Troponin-I inhibits 
ATPase activity and thus inhibits the binding of actin and myosin and this inhibition is 
reversed by calcium attachment to Troponin-C.3 
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There are three tissue-specific subtypes of Troponin-T: 
T1 in slow skeletal muscle fibers 
T2 in cardiac muscle fibers (cTnT) and 
T3 in fast skeletal muscle fibers.4 
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The clinical laboratories use assays to detect cTnT (cardiac Troponin-T). Hence, its 
detection is specific for cardiac origin. Specificity to cardiac origin is close to 98%. Current 
methods of cardiac Troponin-T assay have only 2% cross-reactivity to skeletal Troponin.  
MECHANISM OF TROPONIN-T RELEASE DURING ISCHEMIC 
EVENTS: 
Myocardial ischemic injury, either reversible or irreversible, causes increased 
permeability of myofibrils and thus Troponin complexes are released into circulation. Thus 
Troponin-T or Troponin-I assessment in blood indirectly detects myocardial ischemic 
damage. 
Troponin is bound mainly to myofibrils (94%) and the rest 6% is cytosolic. When 
myocardial injury occurs, there is rapid early release of cytosolic Troponin-T and late 
gradual prolonged release from myofibrils. This affects the kinetics of Troponin-T release 
(Biphasic release pattern). The dissociation of that major portion that is compartmented in 
myofibrils is a time-consuming process and hence its long-lasting release. Though the 
serum half-life of Troponin-T is 120 minutes, this late and slow release of Troponin-T into 
the circulation is the reason for its values to remain high for upto 7-14 days.5 
Myocardial depressive factors that are released in the setting of inflammatory states 
(e.g. sepsis, CPB) cause degradation of Troponin molecules into smaller molecules which 
escape into the circulation because of increased membrane permeability. 7  
ELIMINATION OF TROPONIN-T FROM BODY: 
The exact mechanism of Troponin-T elimination from the body is unknown. It has 
been postulated that they are cleared by reticuloendothelial system (given the large size of 
these molecules). These large molecules are fragmented into small molecules and are 
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subsequently excreted by the kidney. A portion of them are also degraded by vascular 
endothelium.8 
CAUSES OF ELEVATION OF TROPONIN-T IN CARDIAC 
SURGERY: 
1. Direct surgical trauma, 
2. Inadequate myocardial protection,  
3. Reperfusion injury, 
4. Myocardial infarction and  
5. Cardioversion-defibrillation shocks 
Other causes of elevations of Troponin-T 7: 
1. Acute pulmonary embolism 
2. Acute pericarditis 
3. Acute of severe heart failure 
4. Sepsis and/or shock 
5. Myocarditis 
6. Hypertrophic cardiomyopathy 
7. Type A aortic dissection 
8. Strenuous exercise 
9. Renal failure 
10. Cardiac contusion after blunt chest wall trauma, external cardiac massage 
11. False positive troponin- Heterophilic antibodies, Rheumatoid factor, Fibrin clots, 
Microparticles,  Analyser malfunction 
There are four different theories that explain the persistent basal elevation of Troponin-
T in patients with chronic kidney disease and skeletal muscle disease.8 
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1. Theory of re-expression: in above said disease conditions, the cTnT re-expression 
occurs (a remembrance of early fetal form of expression)20  
2. Theory of cross-reactivity: the skeletal form of Troponin-T cross-reacts with cTnT 
in the first generation assay methods. However, this is avoided in second generation 
assays where more specific antibodies are used. 
3. Theory of isoforms: minimal amounts of isoforms of cTnT are expressed in skeletal 
muscles as well. 
4.  The kidneys have a role in clearance of Troponin-T from the body.21  
TROPONIN-T IN CARDIAC EVALUATION: 
The amino acid sequences of cardiac and skeletal forms of Troponin-T and I are 
different significantly and hence these two assays are useful in cardiac evaluation. But the 
structures of Troponin-C of both cardiac and skeletal muscle fibers are similar and so the 
assay of Troponin-C is not useful clinically. 
ESC/ACC committee has documented that any degree of myocardial necrosis will 
impair the clinical course of the patient and that there is no threshold value of elevated 
Troponin-T below which it can be considered harmless.  
It has been proved that even less than 1 gm of myocardial necrosis is detected by 
Troponin-T assay.7  
SENSITIVITY OF TROPONIN-T:  
Troponin-T is 95% sensitive for cardiac ischemic necrosis as it detects even subclinical 
levels of myocardial ischemic events (“microinfarcts”), which are not evident on ECG or 
ECHO findings. 
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SPECIFICITY OF TROPONIN-T: 
 With current methods of Troponin-T assay (2nd generation assays), the specificity of 
Troponin-T to cardiac origin is close to 98%.11 
PATTERN OF ELEVATION OF TROPONIN-T: 
Troponin-T level in blood starts to rise after 3-4 hours and peaks at 18-24 hours and lasts 
for 7-14 days in blood.10 
PREVIOUS STUDY RESULTS: 
Several studies have been conducted in the past in various parts of the world in 
similar manner as this study) to find out the significance of postoperative Troponin-T 
elevation.12 Most of such studies have demonstrated positive correlation between higher 
Troponin-T values and increased postoperative morbidity and mortality. These studies have 
also derived a cut-off value for Troponin-T levels in post-cardiac surgery patients beyond 
which the morbidity and mortality is increased. 
Most of such studies have been done on patients undergoing CABG. But, since 
adequacy of revascularisation and perioperative MI are major determinants of Troponin-T 
elevation in these kinds of patients, we didn’t want to conduct a study on patients 
undergoing CABG surgery (because this study is aimed to find out whether Troponin-T in 
postoperative period reflects the inadequacy of myocardial protection). If, in this study, we 
had included CABG surgeries also, perioperative MI would have been a major confounding 
bias. Also, those patients who have evidence of significant Coronary Artery Disease were 
excluded from the study by conducting Coronary Angiogram in patients over 40 years of 
age. Those with ECG evidence of CAD were also excluded from the study. 
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Some other studies have been undertaken with similar intent, but by including 
various kinds of cardiac surgeries in a single study. Various kinds of cardiac incisions in 
various parts of the heart and various lengths of incisions cause various levels of elevation 
of Troponin-T. Atrial incisions cause lesser level of Troponin-T elevation when compared 
to incision on ventricular muscle. Hence, mitral valve replacement surgery (MVR) alone 
was taken for this study, by which we have avoided an important bias. 
Sigismond Lasocki, analysed 502 consecutive patients who underwent various 
cardiac surgical procedures, and found that high Troponin-T value is an independent risk 
factor for postoperative mortality.13 
Hugo A katus et al, performed a study on 338 patients and showed that Troponin-T 
improves the efficiency in diagnosis of myocardial ischemia when compared to CK-MB. 
(sensitivity of Troponin-T was 94% and that of CK-MB 63%)13 
 Bernard L Croal, conducted a study in 1365 patients and showed that elevated levels 
of Troponin-T at 24 hours after surgery was associated with increased short-term, mid-term 
as well as long-term mortality.14  
James L Januzzi conducted a study on 224 patients to find out the significance of 
CK-MB and Troponin-T in post cardiac surgery patients. He found that elevated Troponin-
T level correlated well with post operative complications whereas the correlation of CK-MB 
was poor.15 
Joost Swaanenburg conducted a study on 123 patients undergoing various cardiac 
surgeries and found that when cross clamp time extends beyond 1 hour, there is rapid rise in 
Troponin-T levels. He also demonstrated that Troponin-T elevation levels depend on the 
type of cardiac surgery. Off-pump CABG surgeries did not cause a significant rise in 
Troponin-T level whereas on-pump CABG and valve surgeries produced Troponin-T 
elevation. Of all kinds of surgeries, valve surgeries produced highest levels of Troponin-T.15  
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H A Katus et al conducted a study in 56 patients and found that Troponin-T level 
raises correspondingly with cross clamp time.16  
Russel Hirsch et al, conducted a study on 56 pediatric patients and found that 
Troponin-T at 1 hour after surgery indicates the extent of myocardial damage and was 
predictive of difficult recovery.17  
Steven E. Lipshultz et al, conducted a study on 51 pediatric patients and showed that 
elevated Troponin-T levels are predictive of myocardial damage and its level correlates with 
increased morbidity and mortality.18  
Luc Jacquet et al, conducted a study on 117 patients and found that Troponin-T 
estimation after CABG was helpful to detect perioperative ischemia or MI and was superior 
to ECG findings in detecting early and mild ischemia.19  
OTHER METHODS ASSESSMENT OF ADEQUACY OF 
MYOCARDIAL PROTECTION: 
Adequacy of myocardial protection cannot be assessed directly but can only be 
assessed by indirect methods like ECG, Echocardiogram and by various factors that are 
influenced by myocardial protection. 
ECG:  
Though postoperative ECG may detect a significant myocardial ischemic injury by 
ST-T changes, minimal global ischemic injury is not always sufficient enough to cause such 
changes in ECG. Patchy distribution of areas of necrosis and partially viable myocardium 
amidst normal areas of myocardium is common after prolonged ischemic time. 
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ECHO: 
Regional wall motion abnormality may be detected by transthoracic ECHO (TTE) 
or, more accurately, by trans-oesophageal ECHO (TEE). But this finding occurs only in 
severely damaged myocardium. Ejection fraction in the postoperative period, when 
compared to preoperative status, may provide a clue to significant ischemic damage, though 
it may be influenced by various other factors like inotropic supports, volume status, residual 
anatomic lesion, patient-prosthesis mismatch, fever, sepsis, etc. 
Functional status: 
NYHA classification of functional status is a good tool to compare pre and 
postoperative status. But the classification is based on one’s own subjective feeling of 
wellness and it is not sensitive and specific enough to detect minor or even moderate 
degrees of myocardial ischemic injury. A poor NYHA status postoperatively may be due to 
not only cardiac function impairment but also pulmonary functional status, renal function, 
skeletal muscle system, central nervous system, liver function, hemoglobin level, nutritional 
status, psychological motivation, etc. 
Mortality rate: 
Severe myocardial ischemic injury may be a cause of or sometimes a precipitating 
factor for postoperative mortality. In studies involving large number of patients, it may be 
found that Troponin-T elevation is a risk factor for postoperative death occurring within 1 
month. But, since the mortality rates of open heart surgeries are generally very low in most 
of the cardiac surgical centers, the use of mortality rate, as an indicator of poor myocardial 
protection, is difficult in small scale studies. 
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CK-MB:  
Since these enzymes are found in skeletal muscle as well, the assay of CK-MB is not 
sufficiently specific for cardiac origin. CK-MB used to be the commonly used cardiac 
marker earlier, till the arrival of Troponin-T assay. This test was widely used by 
cardiologists in acute coronary syndromes before the advent of Troponin-T. Since 
Troponin-T assay is now available in most of the hospitals, the use of CK-MB has come 
down.15 
CK-MB is not specific to cardiac muscle because there is significant overlap 
between cardiac and skeletal muscle CK structure. Hence CK-MB assay is not as reliable as 
Troponin-T for assessing extent of myocardial ischemic injury. 
It has been proved in studies that even with a transient myocardial ischemia which 
causes “reversible” myocardial damage, Troponin-T is released into circulation. This proves 
the high sensitivity of Troponin-T assay in detecting myocardial injury.7  
INTRA-OPERATIVE MONITORING OF MYOCARDIAL 
PROTECTION: 
These are the techniques used to monitor both adequacy and uniform distribution of 
cardioplegia. Myocardial temperature and pH monitoring are the two mainstays of intra-
operative monitoring of adequacy of myocardial protection.1 
Myocardial Temperature monitoring: 
Thermocouple needles inserted into the myocardium is the most commonly used 
technique. Usually a single needle is inserted into the septum and the temperature is 
monitored. The adequacy of cardioplegia solution is dictated by the temperature attained at 
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the septum. When rewarming of the septum occurs, it becomes an indication for repeat 
cardioplegia. 
Myocardial pH monitoring: 
pH monitoring is not used widely but it is a useful tool to monitor adequacy of 
myocardial protection. pH monitoring can be done either directly by small pH meters 
inserted through the myocardium or indirectly through measurement of pH in coronary 
sinus effluent. 
Research level assessment of adequacy of myocardial protection: 
For experimental purposes, myocardial biopsy can be taken from animals that are 
subjected to aortic cross clamping either by transvenous route when the animal is alive or 
by postmortem studies when the animal is sacrificed. In humans, postmortem biopsies of 
myocardium may be examined for patchy muscle necrosis, myofibrillar degeneration, etc.  
for research purposes. 
IMPORTANCE OF OUR STUDY: 
Since poor myocardial protection and the injury sustained due to ischemia-
reperfusion injury has its effects in both immediate postoperative period (unstable 
postoperative period, prolonged ventilator support, increased inotropic support, prolonged 
ICU stay, increased mortality rate) as well as in long term results (poor functional class, 
poor LV function, early mortality), its avoidance will result in overall improvement in 
patient’s postoperative status and also a reduction in mortality. The identification of 
presence of myocardial ischemic injury and its extent in every individual patient will help to 
self-evaluate the techniques we follow in myocardial protection. If there is a single test 
which detects both the presence and the severity of myocardial injury specifically and with 
100% sensitivity, that test can be used to evaluate all patients postoperatively both to find 
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out the cause of poor hemodynamic status as well as for research purposes to evaluate the 
efficacy of different methods of myocardial protection and different kinds of cardioplegic 
solutions.  
Of all the tests available so far in this category, only Troponin-T evaluation has 
highest sensitivity and specificity.9 But the important factor of surgical myocardial injury 
complicates the practical use of this test. Any surgical incision on the heart causes release of 
Troponin-T into the circulation and hence Troponin-T elevation is universal after any 
cardiac surgery. It is important to differentiate Troponin-T elevation due to ischemic 
damage from that due to surgical incision. Many scientific papers have been published 
about the significance of Troponin-T values in postoperative period. These papers have 
proved a fact that the rise of Troponin-T in postoperative period follows a predictable 
pattern i.e. the initial rise upto a certain level can be considered to correspond to surgical 
injury and later phases of elevation beyond this level indicates the level of myocardial 
ischemia-reperfusion injury. 
The significance of Troponin-T after cardiac surgery still remains undefined. 
This study that we have undertaken is another attempt to find out if the Troponin-T 
level predicts the severity of ischemic injury differentiating it from surgical injury based on 
a cut-off value between the two. In other words, our aim was to find out if Troponin-T 
elevation in post-cardiac surgery patients is predictable or is erratic without any 
predictability. (by the word “predictable”, we mean “predictable level of troponin-T 
consistent with the severity of ischemic myocardial injury”) 
USEFULNESS OF TROPONIN-T IN CARDIAC SURGICAL 
PATIENTS: 
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Troponin-T should be routinely used after open heart surgeries for following 
reasons:  
1. The value of Troponin-T in a postoperative patient tells us about the efficacy of 
myocardial protection strategies applied in that patient and to review any deficiencies in 
myocardial protection. In a long term basis, this would help improve the myocardial 
protection strategies that we follow in our hospital. 
2. This test is useful to find out the cause of difficult postoperative period in some 
patients (unexplained postoperative hemodynamic instability). 
3. Identification of high risk patients by high Troponin-T values may direct us to 
take special care in these individuals so as avoid morbidity or mortality. More duration of 
intensive care monitoring, special interventions and efficient use of economic resources 
may be directed to these high risk patients. By these measures, the patient outcome may be 
improved. 
THE NORMAL CUT-OFF VALUES FOR TROPONIN-T: 
The cut-off values for Troponin-T for detecting acute cardiac ischemic events (non-
surgical) are well known but these values are not applicable for cardiac postoperative status 
because Troponin-T levels are invariably elevated in all patients undergoing cardiac 
surgery, irrespective of the complexity of surgery. Hence we need to find out the cut-off 
value for Troponin-T in post cardiac surgery status (specifically for each type of cardiac 
surgery). Below this cut-off level, the values would indicate incisional elevation and beyond 
this, would indicate ischemic necrosis. 
 The standard textbook in cardiology, Hurst’s The Heart, denotes the normal and 
abnormal values for Troponin-T as below: 
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 upto 0.01ng/ml (normal) 
 Upto 0.09 (borderline) 
>0.1 (Indicative of myocardial infarction). 
But, these values are not applicable to patients who have undergone cardiac surgery 
as the postoperative values of Troponin-T are usually much exceeded than 0.1ng/ml. Hence, 
new cut-off values should be derived for cardiac surgical patients, (more specifically, cut-
off values for each type of cardiac surgery). Many previous studies have found that when 
the levels go beyond 13ng/dl, the mortality rate goes steeply high. 
TROPONIN-T ASSAY METHOD: 
Troponin-T in blood is assessed by immunometric one-step sandwich technique. 
The testing is based on polyclonal antibodies specifically developed against epitopes on 
cTnT molecule. These epitopes differ significantly between cardiac Troponins (cTnT) and 
skeletal Troponins. 
 In this method, polyclonal antibody to epitopes of cardiac Troponin-T is 
immobilized in polyvinylchloride test tubes. Troponin-T standards (control) or serum 
samples and peroxidase-labeled anti-Troponin-T monoclonal antibody is added to these test 
tubes. When incubated, Troponin-T molecules are adsorbed onto polyclonal antibody 
(which are in solid-phase) and to monoclonal antibody-enzyme complex (which are in 
liquid phase). The unbound peroxidase-labeled monoclonal antibodies are removed by 
washing. Now, the antibody-enzyme complexes which are adhered to the tubes correspond 
to Troponin-T level in that patient. The amount of enzyme immobilized is the direct 
measure of bound Troponin-T and this is measured by spectrophotometer (by peroxidase 
substrate conversion at 405 nm wavelength).13  
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DETAILS OF THE STUDY 
The study was intended to find out if Troponin-T assay in postoperative status was 
useful as an indicator of myocardial ischemic injury sustained during aortic cross clamp and 
cardioplegic arrest. 
To analyse the correlation between myocardial ischemic injury and Troponin-T level, 
we decided to correlate the following variables with the level of Troponin-T. 
1. Aortic cross clamp time 
2. CPB time 
3. CP interval time 
4. Longest Time Off Cardioplegia (LTOC) 
5. Average Time between each cardioplegia (ATOC) 
6. Postoperative duration of ventilation 
7. Duration of ICU stay 
8. Inotropic support required 
9. Post op ECG evidence of myocardial ischemia 
10. ECHO evidence of myocardial ischemia 
11. Clinical evidence of failure (evidence of pulmonary edema, requirement of excess 
diuretics, etc) 
12. Postoperative functional status(NYHA) 
13. Mortality  
The mortality rate following open heart surgeries are too low to be used as a marker of 
poor surgical results in a small scale study. Hence, we depend on other evidences of 
myocardial injury to establish correlation between poor myocardial protection and poor 
postoperative outcomes. 
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EXCLUSION CRITERIA: 
Those patients with severely depressed cardiac function (EF<40%) require special 
care during myocardial protection measures. And also there is a rise in Troponin-T level in 
blood of patients in failure. Hence these patients were excluded from the study. 
As already mentioned, those patients who have evidence of coronary artery disease 
(ECG or Echo evidence) were excluded from the study since perioperative MI may cause a 
rise in Troponin-T elevation. Patients older than 40 years are routinely evaluated with 
coronary angiogram and those who have significant coronary artery disease are also 
excluded from the study. 
Patients who had already undergone Closed Mitral Commissurotomy (CMC) and 
now undergoing mitral valve replacement surgery were excluded, as during dissection of 
adhesions, direct surgical injury to myocardial tissue occurs. 
Patients with more than mild AR were also excluded. 
Since Troponin-T elevation occurs in patients with chronic renal failure due to 
unknown reasons (explained below), CKD patients were excluded from the study. 
Patients with elevated liver function tests were also excluded since the excretion of 
Troponin-T may be affected in these patients.7  
THE TIMING OF THE TROPONIN-T ESTIMATION IN THIS STUDY: 
Since Troponin-T levels usually reach their peak values at around 18-24 hours after an 
ischemic event, and then start to decline, a single estimation of its value at 24 hours is used 
in this study. Most of the previous studies to evaluate the correlation of Troponin-T with 
myocardial ischemic time have used this same kind of testing (i.e. a single measurement at 
24 hours after surgery, though some of the studies have done Troponin-T assay at 20 hours) 
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It has been proved in studies that even with a transient myocardial ischemia which causes 
“reversible” myocardial damage, Troponin-T is released into circulation. This proves the 
high sensitivity of Troponin-T assay in detecting myocardial injury.7  
THE STANDARD STEPS OF A MITRAL VALVE REPLACEMENT 
SURGERY IN OUR HOSPITAL: 
Under General Anesthesia, median sternotomy is done. Thymus is mobilized. 
Pericardial cradle is created. Cardiopulmonary bypass is established with bicaval and aortic 
cannulae after heparinisation. Alpha-stat acid-base management protocol is followed. 
Heparin is administered at a dose of 300 U/kg body weight. Activated Clotting Time (ACT) 
is tested after 5 minutes and it is maintained above 480 sec throughout cardiopulmonary 
bypass. Priming solution (for an adult) is prepared by adding 500ml of Ringer-Lactate 
solution + 500ml of Hetastarch . 100ml of Inj.Mannitol (20%), 50 ml of Inj.Sodium 
Bicarbonate and 2ml of Inj.Dexamethasone are added to this solution. Heart is cooled to 32 
degree Celsius gradually over 5 minutes. Aorta is cross clamped at 32 degree C. Antegrade 
cardioplegia is administered through a 12 Fr cannula in the ascending aorta with digitally 
guided aortic root pressure, for a duration of 2-3 minutes. Cardioplegic solution is prepared 
with Inj.Plegiocard. 4:1 blood cardioplegia is prepared. This solution is administered at 4 
degree Celsius. The left atrium is opened to avoid distension of the left heart. After 
cardioplegia administration and electromechanical quiescence of the heart is obtained, ice 
slush is poured into pericardial cavity and its spread underneath the heart is ensured. 
Cardioplegia is repeated every 20-30 minutes or upon seeing the cardiac activity, depending 
on whichever is earlier. Ice slush is applied after every cardioplegia administration. When 
the surgery is predicted to be over within 10 minutes ice slush is avoided during the last 
cardioplegia. Core cooling is done upto 28 degree Celsius. Once left atrium is opened, any 
clot in the cavity or in LA appendage is removed. LA appendage exclusion is done, in 
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patients with LA/LA appendage clot, with circumferential sutures taken on endocardial side 
of LAA using 3-0 prolene. Anterior mitral leaflet (AML) and posterior mitral leaflet and 
subvalvular apparatus are examined. PML is fully or partially preserved if anatomy is 
favorable. AML and its chordate are removed. Intermittent horizontal mattress sutures are 
taken from atrial side (so that the pledgets lie on atrial side and the valve lies intra-
annularly) using 2-0 Ethibond pledgetted sutures with 13 mm round-bodied half circle 
needles. The valve sizer is used to measure the annulus size and valve is selected according 
to it. Selection of tilting disc or bileaflet valve depends on surgeon’s preference as well as 
the availability of valve at that time (valves being supplied by the TNMSC). All the suture 
needles are subsequently passed through the sewing ring of the prosthetic valve and the 
valve is parachuted to the annular position. The sutures are tied securely with 5 knots. After 
mitral valve implantation, the mobility of the prosthetic valve leaflet(s) is tested. Any 
subvalvular chordae or other structure interfering with the movement of the leaflet is cut 
away or else the valve is rotated within the sewing ring such that the mobility is 
unrestricted. Usually, a tilting disc valve is positioned with its larger orifice facing 
posteriorly if PML was excised and anteriorly if PML is preserved. A bileaflet valve is 
positioned in anti-anatomical position. Left atrium is closed in two layers using 3-0 prolene 
and before tying the last knot, the LA is de-aired. The CP cannula in ascending aorta is used 
for de-airing and blood is allowed to be ejected through this for 5 minutes and later it is 
connected to pump with 300ml/min reverse flow. Aortic cross clamp is removed with head 
end down and with carotid compression and with the pump flow reduced to 0.5 lit/min. This 
flow rate is gradually increased to normal flow over 2-3 minutes. Defibrillators are used 
when necessary. The heart is supported with pump for a duration of 1/3rd of total cross 
clamp time. Heart is weaned from cardiopulmonary bypass gradually. CP cannula, SVC and 
IVC cannulae are removed and Protamine infusion is started. When half of the protamine 
infusion is completed, aortic cannula is removed. Protamine dose is calculated according to 
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the total dose of heparin given during the surgery (1.2mg for 1mg of heparin) also 
considering the ACT value and the time interval between heparin administration and 
protaminisation. Intercostal and/or mediastinal drainage tubes are placed. After hemostasis, 
sternum is approximated with 6 metric steel wires (in an adult); subcutaneous layer 
approximated with 2-0 Vicryl and skin with subcuticular absorbable sutures. The inotropic 
support is started only when it is indicated according to the hemodynamic status and not on 
a regular basis. Postoperatively, patient is shifted to Intensive Care Unit where each patient 
is cared by a single nurse. 
CARDIOPLEGIC METHOD FOLLOWED IN OUR INSTITUTION: 
 Antegrade, intermittent, cold and blood cardioplegia is the routine cardioplegia 
method followed in our institution for all cases of Mitral Valve Replacement (MVR) 
surgeries. 4:1 blood cardiolplegia is administered at a dose of 20ml/kg for first time and 
then 10ml/kg subsequently. 
ANESTHESIA: 
Patients are given premedication and pre-operative antibiotics 30 minutes before 
surgery. Induction is done Inj.Thiopentone and Inj. Fentanyl is used as a narcotic. 
Inj.Vecuronium is used for paralysis. Inhalant anesthetic, Isoflurane is used at 1MAC. It has 
been proved in studies that Isoflurane has pre-conditioning effect on the heart and its use is 
associated with lower postoperative Troponin-T levels. 
POST-OPERATIVE CARE: 
 Patients are monitored in cardiothoracic ICU where each patient is monitored by a 
single nurse. The team leader of the ICU is a cardiothoracic surgeon. Inotropic supports are 
not a routine protocol in our hospital but are started only on the basis of hemodynamic 
status. Patients are extubated when they are hemodynamically stable, fully alert and there is 
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no significant post-operative bleeding. Some of the surgical units have a protocol to 
extubate them only on the 1st post-operative day in the morning hours. Intravenous 
unfractionated Heparin (5000 units) is administered 10 hours after surgery if there is no 
significant drain and Acinocoumerol is started in the evening of 1st postoperative day. 
Patients are monitored in this ICU for minimum 2 days after surgery. When patient is 
stable, patient is shifted to step-down ICU where each nurse monitors 5 patients.  
TROPONIN-T LEVEL ESTIMATION 
Troponin-T analysis was done when 24 hours had passed after surgery. For this 
purpose, 2ml of blood is collected from the patient and is sent to the lab in a test tube (The 
cost of the test was borne by the prinicipal investigator). The testing was done in a private 
lab (Hi-Tech Labs) and all the 51 samples were analysed in the same laboratory. The blood 
sample was centrifuged immediately and the serum was used for estimation of Troponin-T 
level by Electro-chemiluminescence (ECLIA) method. The results are given in ng/ml units. 
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MATERIALS AND METHODS 
This prospective study was undertaken as an analytical study to find out the 
significance of post-operative Troponin-T level as a marker of myocardial ischemic injury 
in mitral replacement surgeries, in cardiothoracic surgery department of Rajiv Gandhi 
Government General Hospital, Chennai-600003, from April 2012 to March 2013. Hospital 
Ethical Committee approved this study to be conducted in Rajiv Gandhi Govt General 
Hospital. Patients were well informed about the nature of the study and consent was 
obtained in written format for withdrawal of 2 ml of blood and Troponin-T estimation. 
INCLUSION CRITERIA 
 Patients who were to undergo Mitral Valve Replacement Surgeries during the above 
said period were included in the study. Both Rheumatic and Non-rheumatic pathologies 
were accepted for the study. Both stenotic (MS) and regurgitant (MR) lesions (or a 
combined of two) were included. Only patients aged more than 13 years were included in 
the study. 
EXCLUSION CRITERIA 
1. Patients who have evidence of coronary artery disease 
2. Re-do mitral valve surgeries (Post-CMC) 
3. Poor left ventricular function (EF<40%) 
4. LV diastolic dimension >7.0 cm 
5. Renal failure 
6. Hepatic failure 
7. Patients with more than mild AR (aortic regurgitation) 
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METHODOLOGY 
 The preoperative, per-operative and post-operative details were personally collected 
by the investigator by direct communication with the patient and by assisting during the 
surgery and also following-up the patient in post-operative period. The data regarding 
significant events after discharge of the patients were also traced by phone communication 
and by follow-up in the out-patient department. 
 The information and data collected for each patient were entered in the proforma 
specially designed for this study. 
 The following information/data were collected from each patient. 
1. Name, age, sex, IP number, Date of admission 
2. ECG and Echo findings- Echocardiogram is done both by cardiologists and 
cardiothoracic surgeons. 
3. Pre-operative functional class (NYHA classification was used) 
4. Presence or absence of Atrial fibrillation 
5. Total cross clamp time 
6. Number of times cardioplegia was administered 
7. Longest time off cardioplegia (Longest time between any two consequent 
cardioplegia) 
8. Average time interval of cardioplegia (time interval between consequent 
cardioplegia doses) 
9. Cardiopulmonary bypass (CPB) time 
10. Requirement of DC shocks: it has been proved in studies that, though external 
defibrillator application causes elevation of Troponin-T, internal cardioversion does 
not cause any such elevation. 
34 
 
11. Requirement of post-operative inotropic support. This was classified into three 
categories for the purpose of ease of calculation and better understanding. 
Drug Minimal Intermediate High 
Dopamine <5ug/kg/min 6-10ug/kg/min >11ug/kg/min 
Adrenaline <0.05ug/kg/min 0.06-0.1ug/kg/min >0.11ug/kg/min 
Isoprenaline <0.05ug/kg/min 0.06-0.1ug/kg/min >0.11ug/kg/min 
 
12. Duration of inotropic supports (in days) 
13. Duration of postoperative ventilation (in hours) 
14. Duration of ICU stay (in days) 
15. Duration of hospital stay after surgery (in days) 
16. ECG or echo evidence of myocardial ischemia. A new q wave of more than 0.1 mV, 
or ST-T changes in two consequent leads suggestive of ischemia were taken as 
positive evidences of perioperative MI or significant ischemic injury. ECG 
interpretation was done by cardiologists in association with cardiothoracic surgeons. 
Postoperative echo was performed by cardiologists in the immediate post-op period 
if patient is hemodynamically unstable but only after 7 days if patient is stable. 
17. Clinical evidence of failure: patient was examined by the investigator for presence 
of any signs of cardiac failure like, pulmonary crepitations, pedal edema, 
tachycardia, dyspnoea, mental obtundation, cold peripheries, high CVP, reduced 
urine output, etc., Patient’s symptoms were also taken into account.  
18. Ejection fraction of left ventricle: this was categorized into three varieties.  
EF 41-50% - mild dysfunction  
EF 31-40% - moderate dysfunction 
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EF <30% - severe dysfunction 
19. Postoperative NYHA status: patients were classified into 3 categories: those who got 
improved after surgery and those who didn’t get any improvement and those who 
got worsened after surgery. 
20. Requirement of IABP 
21. Mortality: the cause of mortality was assessed and was ascertained whether it is due 
to cardiac cause or non-cardiac cause. 
 
ANALYSIS METHODS 
Data were analysed with the help of a doctor specialized in statistics. 
Descriptive statistics: mean+ standard deviation was calculated. 
 Correlation for continuous variables was done. Chi-square/Fischer’s test was done 
for categorical variables. Independent  ‘t’ test was done to look for significant different 
between 2 groups. ROC (Receptor Operator Characteristic) curve was used to determine the 
cut-off level of troponin-T at which levels, the postoperative complications occur more. By 
ROC curve, the level was fixed at 0.6 ng/ml. 
Data was entered in Microsoft Excel Spreadsheet and was analysed using SPSS 
(Statistical Package for Social Science) version 16. 
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RESULTS 
AGE DISTRIBUTION: 
The Age group extended from 15 years to 61 years.  
Mean age was 32.92 + 12.02 years and median age was 32 years.  
 
SEX DISTRIBUTION: 
Among the study participants, 75 % were females 
 
 
LESION-WISE CLASSIFICATION: 
16 (31.4%) patients had mitral stenosis 
13 (25.5%) patients had mitral regurgitation 
22 (43.1%) patients had both mitral stenosis and regurgitation 
17 (33.3%) patients had pre-operative atrial fibrillation 
2  (3.9%) patients had LA clot. 
25 
75 
MALE
FEMALE
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NUMBER OF CP (NUMBER OF TIMES CARDIOPLEGIA WAS 
ADMINISTERED):  
1 – 1 (2%) 
2 – 30 (58.8%) 
3 – 18 (35.3%) 
4 – 2 (3.9%) 
Average: 2.4 
Median: 2 
For those patients, who received 1 or 2 cardioplegias, the average Troponin-T level was 
0.676 ng/ml. 
For those, who received 3 or 4 cardioplegias, the average troponin-T value was 0.706 ng/ml. 
 
TOTAL CROSS CLAMP TIME:  
Average: 68 + 2 minutes 
Median: 70 minutes 
Longest: 87 minutes 
Shortest: 28minutes 
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Aortic cross clamp time Number of patients % 
Average 
Troponin-T value 
for this group 
<70 minutes 27 52.9% 0.567 ng/ml 
> 70 minutes 24 47.1% 0.821 ng/ml 
Total 51 100% 
 
 
The above table shows that Troponin-T levels are elevated with increasing duration of 
aortic cross clamp time. 
 
LONGEST TIME OFF CARDIOPLEGIA (LONGEST INTERVAL 
BETWEEN CARDIOPLEGIAS IN A SINGLE PATIENT): 
Mean:    28 + 1 minutes 
Median:  28 minutes 
Longest:   38 minutes 
Shortest:  22 minutes 
Longest Time Off 
Cardioplegia 
Number of 
patients % 
Average 
Troponin-T value 
for this group 
< 28 minutes 29 56.8% 0.661 ng/ml 
>28 minutes 22 43.1% 0.723 ng/ml 
Total 51 100 
 
 
The above shows that when the interval between two cardioplegias is prolonged, Troponin-
T levels are simultaneously elevated. 
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AVERAGE TIME INTERVAL OF CARDIOPLEGIA: 
Mean:   26 + 1 minutes 
Median:  26 minutes 
Maximum :  34 minutes 
Minimum :   21 minutes 
Average interval 
between cardioplegias 
Number of 
patients % 
Average 
Troponin-T value 
for this group 
<  26 minutes 27 53% 0.594 ng/ml 
> 26minutes 24 47% 0.739 ng/ml 
Total 51 100% 
 
 
The above table shows that when the interval between two cardioplegias is prolonged, there 
is increased troponin-T release. 
Lichtenstein et al, has used these two parameters in his study, to assess the efficacy of 
intermittent warm blood cardioplegia. 
LTOC- Longest Time Off Cardioplegia (Longest single ischemic time in a patient) 
PTCO- Percentage Time Off Cardioplegia25 
 
CPB DURATION: 
Average CPB duration:  97 + 2 minutes 
Maximum : 140 minutes 
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Minimum : 57 minutes 
CPB duration Number of patients % 
Average 
Troponin-T value 
for this group 
<97 minutes 21 41.1% 0.658 ng/ml 
>97 minutes 30 58.8% 0.709 ng/ml 
total 51 100 
 
 
The above table shows that when CPB duration is increased, Troponin-T levels are 
elevated. 
 
REQUIREMENT OF INOTROPIC SUPPORTS: 
Inotropic support 
Number of 
patients 
% 
Average 
Troponin-T value 
for this group 
Nil 15 29.4 0.522 ng/ml 
Minimal / Intermediate 30 58.8 0.729 ng/ml 
High 6 11.8 0.894 ng/ml 
Total 51 100  
 
From the above table, it is evident that higher doses of inotropes are required in those 
patients whose Troponin- T values are high. 
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DURATION OF INOTROPIC AGENTS: 
 37 (72.5 %) patients required inotropic for < 2 days. Their average Troponin-T value was: 
0.59 ng/ml. 
14 (27.5) patients required inotropic support for more than 2 days. Their average Troponin-
T value was: 0.93 ng/ml. 
 
Duration of inotropic 
support 
Number of 
patients % 
Average 
Troponin-T value 
for this group 
<   2days 37 72.5% 0.59 ng/ml 
> 2 days 14 27.5% 0.93 ng/ml 
Total 51 100 
 
 
 
DURATION OF VENTILATION: 
44 (86.3%) patients required ventilation for less than 24 hours and their average Troponin-T 
value was: 0.61 ng/ml. 
7 (13.7%) patients required ventilation for more than 24 hours and their average Troponin-T 
value was: 1.17 ng/ml. 
Duration of ventilator 
support 
Number of 
patients % 
Average 
Troponin-T value 
for this group 
Less than 24 hours 44 86.3% 0.61 ng/ml 
More than 24 hours 7 13.7% 1.17 ng/ml 
Total   
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RELATIONSHIP BETWEEN DC SHOCK AND TROPONIN-T 
VALUES: 
9 patients received DC shock after cross clamp release for defibrillation. For those patients 
who received DC shocks, the average Troponin-T value was: 0.85 ng/ml. [Minimum: 0.32 
and Maximum: 1.90] 
42 patients did not receive DC shock.  For those who did not require DC shocks, the 
average Troponin-T value was: 0.65 ng/ml [Minimum: 0.12 and Maximum: 1.88] 
This data suggests that DC shock may be a cause for Troponin-T elevation. 
 
REQUIREMENT OF IABP: 
Only one patient required IABP support in the postoperative period and her Troponin-T 
value was  0.517 ng/ml. 
 
POST-OPERATIVE EVIDENCE OF FAILURE: 
 
 
Postop cardiac 
failure Number % 
Average 
troponin-T value 
for this group 
No 40 78.4 0.607 ng/ml 
Yes 11 21.6 0.981 ng/ml 
Total 51 100  
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40 patients had no evidence of cardiac ischemia/failure (ECG/ECHO/clinical) 
postoperatively and their average Troponin-T value was 0.607 ng/ml.  
11 patients had evidence of cardiac failure (ECG/ECHO/clinical) postoperatively and their 
average Troponin-T value was 0.981 ng/ml. 
 
ICU STAY: 
28 (54.9 %) patients had ICU stay of < 5 days. Their average Troponin-T value was 0.655 
ng/ml. 
23 (45.1 %) patients had ICU stay of > 5 days. Their average Troponin-T value was 0.727 
ng/ml. 
Mean ICU stay – 5.29 days 
Median ICU stay – 5 days 
(The average duration of ICU stay is notably high because it is our hospital policy to retain 
the patients in ICU for an average of 5 days) 
 
ICU stay Number of patients % 
Average 
Troponin-T level 
for this group 
< 5 days 28 54.9% 0.655 ng/ml 
> 5 days 23 45.1% 0.727 ng/ml 
Total 51 100 
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TOTAL HOSPITAL STAY AFTER SURGERY: 
24 (48.8 %) patients (excluding 2 deaths) had < 12 days of hospital stay. 
25 (51.2 %) patients had > 12 days of hospital stay. 
For patients who had less than 12 days of hospital stay, the average Troponin-T value was:  
0.51ng/ml . 
For patients, who had more than 12 days of hospital stay, average Troponin-T value was: 
0.82 ng/ml. 
Total hospital stay after 
surgery 
Number of 
patients % 
Average 
Troponin-T level 
for this group 
< 12 days 24 48.8% 0.510 ng/ml 
> 12 days 25 52.2% 0.820 ng/ml 
Total 49  
 
 
 
NYHA STATUS: 
 
Pre-op NYHA Frequency Percent 
 
II 5 9.8 
III 38 74.5 
IV 8 15.7 
Total 51 100.0 
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Post-op NYHA Frequency Percent 
 
I 17 33.3 
II 25 49.0 
III 7 13.7 
IV 2 3.9 
Total 51 100.0 
 
Postoperatively, 42 patients were in NYHA I/II. Their mean Troponin T value was 0.57 
ng/ml 
7  patients were in NYHA III/IV. Their mean Troponin T value was 1.26 ng/ml. 
NYHA 
(Post- OP) 
Frequency Percent Average Troponin-T for this group 
I&II 42 82.3% 0.57 ng/ml 
III&IV 9 17.6% 1.26 ng/ml 
 51 100%  
 
This table shows that when Troponin-T level is high, the patient is more likely to be in 
NYHA Class III or VI. 
 
MORTALITY:  
Only two patients died in our study population. Their Troponin-T values were 1.570 and 
0.80 ng/ml. 
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DESCRIPTIVE STATISTICS FOR THE VARIABLES: 
 
 
N 
Minimu
m 
Maximu
m Mean 
Std. 
Deviation 
Age 51 15 61 32.92 12.020 
Sex 51 1 2 1.75 .440 
Troponin T 51 .12 1.90 .6881 .41895 
Cross_cramp_time 51 28.00 87.00 68.0784 12.17020 
Cpb duration 51 57.00 140.00 97.5490 13.89146 
LTOC 51 22.00 38.00 28.0000 2.59230 
ATOC 51 21.00 34.00 25.9804 2.59608 
No_of_CPs 51 1.00 4.00 2.4118 .60585 
Duration_of_postop__s
upports 
51 .00 6.00 1.9608 1.79956 
Duration_of_ventilation 51 4.00 120.00 23.8235 24.98536 
Postop_EF 51 40.00 84.00 62.9216 14.17581 
ICU_stay 51 3.00 12.00 5.2941 2.44372 
Total_hospital_stay_aft
er_surgery 
51 7.00 30.00 12.7843 4.80963 
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scatter  diagram for Duration of ventilation vs 
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DESCRIPTIVE STATISTICS FOR THE VARIABLES 
Troponin-T level correlation Pearson correlation Significance 
 (2-tailed) 
Total 
number 
Total cross clamp time 0.394 0.004 51 
CPB duration 0.172 0.228 51 
LTOC 0.124 0.387 51 
ATOC 0.222 0.117 51 
Number of CP 0.134 0.349 51 
Postop supports 0.263 0.062 51 
Duration of postop supports 0.362 0.009 51 
Duration of ventilation 0.376 0.007 51 
Requirement of IABP -0.06 0.684 51 
ECG/ECHO evidence of ischemia 0.429 0.002 51 
Clinical evidence of cardiac failure 0.400 0.004 51 
Post op Ejection Fraction 0.605 0.001 51 
ICU stay 0.033 0.818 51 
Total hospital stay after surgery 0.142 0.319 51 
mortality 0.242 0.087 51 
 
Significant at <0.05 
From the above table, it can be seen that the Troponin-T level has significant correlation 
with the following variables: 
1. Total cross clamp time (p value 0.004) 
2. Duration of postoperative supports (p value 0.009) 
3. Duration of ventilation (p value 0.007) 
4. ECG/ECHO evidence of ischemia (p value 0.002) 
5. Clinical evidence of cardiac failure (p value 0.004) 
6. Postoperative Ejection Fraction (p value 0.001) 
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ROC (RECEIVER – OPERATOR - CHARACTERISTIC) CURVE 
 
Post op_failure Number  
 
YES 11 
NO 40 
 
 
 
 
 
Test Result Variable(s): TroponinT 
Area 
.734 
 
 
Based on the above ROC curve for post operative complications and troponin T levels, the 
optimum cut off level for troponin T is 0.6 ng/ml (Area under the curve is 73.4%) 
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INDEPENDENT T-Test (Test of significance between two groups) 
 
 
 
 
GROUP STATISTICS 
 
 Troponin 
value N Mean 
Std. 
Deviation 
Std. Error 
Mean 
 less than 0.6 29 .4163 .12311 .02286 
above 0.6 22 1.0464 .40156 .08561 
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Levene's Test for Equality of 
Variances 
F Sig. T  
Sig. 
(2-tailed) 
95% Confidence Interval 
of the Difference 
Upper Lower 
TroponinT 32.817 .000 7.991  .00006* .78846 .47157 
*significant at 0.05 level 
 
 
ASSOCIATION BETWEEN CHARACTERISTIC VARIABLES AND 
TROPONIN T VALUE: 
S. No Variables  Troponin T (ng/ml) Total  Chi-square value P value 
< 0.6 > 0.6 
1. Total cross clamp time 
 < 70 8 19 27 4.268 0.039* 
> 70 14 10 24 
2. CPB time 
 < 90 9 0 9 8.291 0.004* 
> 90 20 22 42 
3. LTOC      
 < 25 5 0 5 4.205 0.040* 
> 25 24 22 46 
4. ATOC 
 < 25 13 7 19 0.888 0.346 
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> 25 16 15 31 
5. NO. of CP 
 < 2 17 14 31 0.132 0.716 
> 2 12 8 20 
6. Post OP support 
 Nil  6 9 15 9.009 0.011* 
Minimal/Intermediate 22 8 30 
High  1 5 6 
7. Duration of post OP support 
 < 2 days 23 14 37 0.002 0.964 
> 2 days 6 8 14 
8. Requirement of IABP 
 No  28 22 50 0.774 0.379 
Yes  1 0 1 
9. Post OP failure  
 No  25 15 40 3.659 0.056* 
Yes  4 7 11 
10. Post OP EF score 
 < 50 % 12 0 12 11.905 0.001* 
> 50 % 17 22 39 
11. Mortality  
 No  29 20 49 2.744 0.098 
Yes  0 2 2 
*. The Chi-square statistic is significant at the 0.05 level 
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From the above table, the following impressions are obtained. 
1. The duration of cross clamp time has significant positive correlation with 
Troponin-T levels (p value 0.039) 
2. The duration of CPB also has significant positive correlation with Troponin-T (p 
value 0.004) 
3. Longest Time Off Cardioplegia has significant correlation with elevation of 
Troponin-T (p value 0.040) 
4. High Troponin-T levels has significant correlation with Requirement of high 
doses of inotropes (p value 0.011) 
5. High Troponin-T levels are associated with reduced Ejection Fraction in the 
postoperative period (P value 0.001) 
 
LIMITATIONS OF THE STUDY: 
1. Total number patients studied is less. 
2. It is not a randomized controlled study. 
3. Patients were operated by different surgeons and different surgical units. 
Different surgical units may have different approach in postoperative 
management, for example, early extubation versus late extubation, inotropic 
supports initiation and weaning, etc., 
4. Two patients had trans-septal approach (through right atrium) for mitral valve 
replacement. These two patients had De Vega annuloplasty in addition to MVR. 
Their Troponin-T values were 1.390 and 1.080 ng/ml. In this surgical approach, 
an additional incision is made in the inter-atrial septum. The cause for highly 
elevated values may be due to two incisions (right atrium and septum) and may 
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also be due to excessive retraction or due to the additional procedure (De Vega 
annuloplasty). 
5. One patient had two incisions in the heart. MVR was done through left arial 
incision. Right atrium was then opened to perform De Vega annuloplasty. This 
patient’s Troponin-T was 0.566 ng/ml.  
6. One patient had prolonged hospital stay (30 days) and her Troponin-T value was 
0.871 ng/ml. But the reason for her prolonged hospital stay was due to 
sternotomy wound infection. This is a confounding factor in the variable. 
7. One patient had failed PTMC and subsequently taken up for surgery. It is not 
known whether PTMC causes elevation of Troponin-T, but MVR surgery was 
done only after 1 month. Hence, the previously attempted PTMC is unlikely to 
influence the results of Troponin-T values. Her Troponin-T value was 0.430 
ng/ml. 
8. One patient died on 5th post-operative day. Postoperative echo showed moderate 
to severe aortic regurgitation (preoperative echo showed only mild AR). This 
may be due to unmasking of AR by improved hemodynamics after MVR 
surgery. The patient’s Troponin-T value was 1.570 ng/ml. 
9. Two patients had adherent left atrial clot. They underwent clot removal and left 
atrial exclusion done by internal circumferential sutures with 4-0 prolene. The 
clot removal process or LAA exclusion procedure may be additional sources of 
Troponin-T elevation. Their Troponin-T values were 0.668 and 0.499. 
10. One patient underwent partial maze procedure for atrial fibrillation (using 
electrocautery). Her Troponin-T value was 0.517 ng/ml. 
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DISCUSSION 
Though this study was done with limited number of patients, it clearly shows that 
prolonged cross clamp time is associated with elevated Troponin-T values and that elevated 
Troponin-T values are associated (significant association) with increased morbidity in the 
form of prolonged ventilatory support, prolonged  inotropic support,  requirement of high 
doses of inotropes, postoperative cardiac failure and poor ventricular ejection fraction.  
The per-operative variables that are associated (significantly) with high levels of 
Troponin-T are 1. Prolonged cross clamp time (more than 70 minutes), 2. Prolonged CPB 
time (>90 minutes) and 3. Prolonged CP time (>25 minutes between 2 cardioplegia doses). 
By ROC curve analysis, the cut-off value of Troponin-T, was derived, above which 
the morbidity is significantly increased. The cut-off value is 0.6 ng/ml. (In a study 
conducted by Bernard l. Croal et al, with 1365 patients, and published in “Circulation” 
Journal, 2006;114:1468-1475, the cut-off value derived by ROC curve analysis, was 0.46 
ng/ml and it was proved that the mortality significantly increased above this value).14 
In this study, Troponin-T levels show good correlation with aortic cross clamp time, 
CPB duration and prolonged CP interval as well as postoperative variables like prolonged 
inotropic supports, high dose inotropes, prolonged ventilation and reduced LV function 
(poor EF). Hence, it is clear that Troponin-T is a good tool to assess the adequacy of 
myocardial protection.  
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CONCLUSION 
Troponin-T is a reliable indicator of extent of myocardial injury in cardiac surgical 
patients and is a good armamentarium in the pool of diagnostics in cardiothoracic surgical 
field. 
This test should be used more often than now, in postoperative period, to assess the 
adequacy of myocardial protection. This will have two important implications. 
1. In an individual patient, who is hemodynamically unstable in the postoperative 
period, this test is helpful, in defining the cause of  it. 
2. The efficiency of different techniques of myocardial protection may be 
compared with one another, based on Troponin-T levels. 
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1 Sammandham 56/M 53992 12/9/12 MS(sev) 
PHT-mild 
3 - 127 29 28 84 3 Minimal 1 - 9 - - - 60 5 12 1 - 0.516  
2 Rathinammal 55/F 32957 15/9/12 MS(S) 
MR(mild) 
PHT(sev) 
3 - 93 29 27 60 2 Nil 1 - 8 - - + 70 6 10 2 - 0.304 Lasix infusion+ 
3 Anandhan 52/M 69179 20/9/12 MS(sev) 
PHT(mod) 
2 + 90 26 24 50 2 Minimal 1 - 9 - - - 61 5 15 1 - 0.54  
4 Samanasamary 52/F 156810 18/9/12 MS(sev) 
MR(mild) 
PHT(mod) 
EF(N) 
3 + 86 26 19 60 3 Minimal 3 + 20 - - - 46 4 9 2 - 0.556  
5 Vijayamani 34/F 37602 22/9/12 MS(sev) 
AR(mild) 
TR(sev) 
PHT(sev) 
2 - 81 28 27 61 2 Minimal 1 - 6 - - - 46 4 12 2 - 1.15  
6 Selvi 33/F 76273 24/9/12 MS(sev) 
PHT(mod) 
4 + 101 26 23 71 3 Interme
diate 
5 - 19 - - - N 7 11 2 - 0.269  
7 Latha 18/F 35169 26/9/12 MR(sev) 
No PHT 
4 + 96 23 18 69 4 Nil 3 - 20 - + + 45 4 17 3 - 1.26 RFT 89,3.7 
upto 6 days; 
Dopamine 
started on 6
th
 
day; global 
hypokinesia 
8 Valli 32/F 74932 28/9/12 MS(sev) 
PHT(sev) 
3 - 102 26 23 71 3 high 5 - 120 - + + N 5 5 4 + 1.57 LFT,RFT-N 
AR(mod-sev); 
RV dysfn+; 
Expired on 5
th
 
day 
9 Chithra 40/F 54017 29/9/12 MS(sev) 
PHT(mod) 
3 + 95 31 29 61 2 Nil - - 6 - - - 56 3 10 2 - 0.208  
10 Muniyappan 35/M 61323 3/10/12 MS(sev) 3 - 108 34 27 68 2 Nil - + 4 - - - N 5 14 2 - 0.674  
MR(mod) 
PHT(mod) 
11 Paulraj 48/M 69064 4/10/12 MS(sev) 
PHT(sev) 
3 - 116 26 25 78 3 Minimal 2 - 18 - - - 70 5 10 2 - 0.57  
12 Narayanan 30/M 74171 5/10/12 MS(sev) 
PHT(sev) 
3 - 114 26 24 75 3 Interme
diate 
2 - 19 - - - 65 8 17 2 - 0.662  
13 Chinnaponnu 57/F 85795 8/10/12 MS(sev) 
MR(mod) 
PHT(sev) 
3 - 107 27 26 79 3 High 4 - 48 - - - 64 10 20 3 - 1.36  
14 Suriya 22/F 89892 9/10/12 MR(mod) 
PHT(mod) 
2 - 115 24 22 69 3 Minimal 2 + 20 - - - 70 3 13 1 - 1.9  
15 Nathiya 22/F 90015 19/10/12 MR(mod) 
No PHT 
3 + 136 38 29 89 3 Minimal 2 + 20 - - - N 5 10 1 - 0.566 Devega thro 
RA 
16 Gayathri 15/F 89465 18/10/12 MR(mod) 
PHT(mild) 
3 - 69 24 22 69 2 Nil 0 - 20 - - - N 4 11 2 - 0.843  
17 Vasanth 17/M 88327 22/10/12 MR(sev) 
AR(mild) 
PHT(sev) 
3 - 98 27 24 49 2 Nil 0 - 22 - - - 55 7 10 1 - 0.41  
18 Anjalai 25/F 93573 2/11/12 MR(sev) 
PHT(mild) 
3 + 104 24 21 63 3 Minimal 1 - 20 - - - N 7 10 1 - 0.314  
19 Selvi 32/F 96531 3/11/12 MR(sev) 
MS(mild) 
PHT(mod) 
3 
 
+ 91 36 31 63 2 Interme
diate 
2 - 20 - + - 52 4 7 2 - 0.55 RV dysfn 
20 Mangai 28/F 76758 5/11/12 MS(sev) 
PHT(mod) 
3 + 73 27 25 56 2 Nil 0 - 7 - - - N 5 11 2 - 0.32  
21 Gomathi 22/F 93536 7/11/12 MR(sev) 
AR(mild) 
PHT(mild) 
EF 59% 
3 - 128 27 23 80 3 Minimal 1 - 18 - - - 56 8 12 2 - 0.42  
22 Varalakshmi 40/F 96593 23/11/12 MS(sev) 
MR(mild) 
PHT(sev) 
4 - 83 24 23 51 2 Interme
diate 
2 - 20 - - - 56 3 13 2 - 0.41  
23 Pongala 22/F 89939 20/11/12 MR(sev) 
AR(mild) 
PHT(mild) 
EF 73% 
3 - 114 25 23 72 3 Minimal 2 - 20 - - - 50 6 11 1 - 0.43 PTMC on 
18/10/12 
24 Sasikala 38/F 93541 16/11/12 MR(sev) 
PHT(mild) 
3 - 83 24 23 51 2 Minimal 1 - 16 - - - N 3 15 2 - 0.184  
25 Kumar 25/F 95311 21/11/12 MR(sev) 
MS(mod) 
PHT(mild) 
3 - 95 31 30 63 2 Nil 0 - 6 - - - N 6 13 1 - 0.674  
26 
 
Rani 19/F 90170 28/11/12 MS(sev) 
MR(mild) 
PHT(sev) 
3 - 106 35 33 66 2 Nil 0 - 23 - - - N 5 30 2 - 0.871 Wound 
infection; sec 
suture 
27 Maheswari 35/F 102940 28/11/12 MS(sev) 3 + 100 37 33 67 2 minimal 1 - 20 - - - 64 5 10 2 - 0.636 Atrial flutter+ 
MR(mild) 
PHT(mod) 
EF 65% 
28 Munusamy 18/M 97879 1/12/12 MR(mod) 
MS(mod) 
PHT(mod) 
EF 76% 
3 - 105 31 28 60 2 Nil 0 - 7 - - - N 5 14 2 - 0.69  
29 Gomathi 25/F 108855 3/12/12 MS(sev) 
PHT(mod) 
EF-N 
3 - 99 31 30 64 2 Minimal 1 - 20 - - - 47 3 12 2 - 0.529  
30 Elavarasan 17/M 107053 4/12/12 MR(sev) 
TR(sev) 
EF 70% 
4 - 123 30 27 82 3 Interme
diate 
4 - 22 - - + 60 6 15 2 - 1.39 RA approach; 
De Vega+ 
 
31 Sivagami 36/F 113923 12/12/12 MR(sev) 
PHT(mild) 
EF 69% 
3 + 114 30 24 74 3 Minimal 3 - 6 - + - 43 6 14 2 - 0.115 Mod LV 
dysfunction 
32 Rubavathi 61/F 83761 14/12/12 MS(sev) 
MR(mild) 
PHT(sev) 
3 - 116 34 29 89 3 Interme
diate 
3 - 20 - - - N 7 12 2 - 0.845  
33 Amudha 30/F 113826 13/12/12 MS(sev) 
MR(mod) 
PHT(sev) 
EF 62% 
3 - 83 41 34 71 2 Nil 0 - 6 - - - N 4 14 1 - 0.726  
34 Palaniyammal 35/F 94824 7/12/12 MS(sev) 
TR(sev) 
PHT(sev) 
AR(mild) 
EF-N 
4 - 107 30 27 61 2 Interme
diate 
5 + 45 - - + 56 7 15 3 - 1.08 RAappr 
DeVega+ 
Readmission+ 
35 Ravikumar 27/M 115533 12/12/12 MS(sev) 
PHT(sev) 
3 + 141 32 24 10
0 
4 Nil 0 + 6 - - - N 3 16 1 - 0.668 Organised LA 
clot 
36 Devi 28/F 113844 22/12/12 MS(sev) 
MR(mod) 
PHT(mod) 
2 - 77 27 25 53 2 Minimal 1 - 6 - - - N 5 10 1 - 0.4  
37 Dinesh 15/M 7849 5/2/13 MR(sev) 
No PHT 
EF 67% 
3 - 76 26 22 48 2 Nil 0 + 20 - - - 56 3 14 1 - 1.52  
38 Sasikala 30/F 2006 5/2/13 MR(sev) 
MS(mild) 
PHT(mild) 
EF 60% 
3 + 81 29 28 60 2 Minimal 2 - 20 - - - 54 3 8 1 - 0.527  
39 Mohankumar 38/M 4599 4/2/13 MS(sev) 
PHT(mild) 
2 - 140 31 27 87 3 Minimal 2 - 8 - - - 51 3 14 1 - 0.374  
40 
 
Chellathayee 50/F 5324 2/2/13 MS(sev) 
MR(mild) 
PHT(mild) 
3 + 76 26 22 47 2 High 5 - 96 - + + 40 9 9 4 + 0.8 Reex-0 pod 
for bleed 
Renal fail; exp 
on 9
th
 pod 
41 Sangothai 49/F 118764 15/1/12 MS(sev) 
MR(mild) 
PHT(sev) 
LA clot 
3 - 93 38 34 70 2 Minimal 2 - 20 - - - N 7 9 2 - 0.499 Clot removal 
LAA exclusion 
by prolene 
42 Vijayalakshmi 30/F 116197 4/1/13 MS(sev) 
MR(mod) 
PHT(sev) 
AR(mild) 
EF-N 
4 + 82 32 30 64 2 Minimal 2 - 20 - - - 52 8 13 2 - 0.828  
43 
 
Rani 42/F 123792 1/2/13 MS(sev) 
PHT(sev) 
 
3 - 102 36 35 76 2 High 6 - 48 - + + N 12 18 3  0.993 Septal 
hypokinesia+ 
44 Chinnapillai 35/M 115845 9/1/13 MR(sev) 
AR(mild) 
No PHT 
3 - 68 22 22 45 2 Minimal 2 - 8 - - - 58 6 15 2 - 0.379  
45 Divya 17/F 12273 26/2/13 MR(mod-
sev) 
MS(mild) 
PHT(mod) 
EF-N 
3 - 85 24 25 53 2 Nil 0 + 21 - - - N 5 10 1 - 0.32  
46 Gnanasoudari 29/F 121908 26/2/13 MS(sev) 
PHT(mild) 
EF-N 
3 + 95 27 24 75 3 Interme
diate 
4 - 21 - - + N 6 12 2 - 0.45  
47 Pothumani 29/F 16686 28/2/13 MS(sev) 
MR(mod) 
AR(mild) 
AS(mild) 
PHT(mild) 
3 - 57 25 25 28 1 Minimal 2 - 21 - - - N 4 10 3 - 0.53  
48 Kamala 35/F 13942 27/2/13 MS(sev) 
MR(mild) 
PHT(mild) 
4 - 83 31 28 54 2 Nil 0 + 18 - - - N 5 14 1 - 0.389  
49 Seetha 22/F 6186 1/3/13 MS(sev) 
PHT(mod) 
AR(mild) 
EF-N 
3 - 82 29 27 60 2 High 6 - 56 - + + 56 10 18 3 - 1.88 Re-
intubation+; 
RV dysfn; 
Paradox 
septal motion 
50 Rajeshwari 35/F 16317 6/3/13 MS(sev) 
MR(mild) 
PHT(mild) 
3 - 94 33 29 61 2 Interme
diate 
2 - 22 - - - 58 3 17 1 - 0.478  
51 Amsaveni 42/M 14138 2/3/13 MR(sev) 
MS(mild) 
PHT(mod) 
EF 55% 
4 + 90 25 22 67 3 High 6 - 120 + - + 57 12 25 3 - 0.517 Partial maze 
done; IABP 
2
nd
-4
th
 days 
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INFORMED CONSENT FORM 
 
 
 
Title of the study:   Postoperative Troponin-T as a Marker of Myocardial Ischemic Injury in Mitral 
   Valve Replacement Surgeries 
Name of the Participant:     
Name of the Principal Investigator: Dr. N. Jothilingam 
 Name of the Institution:  Rajiv Gandhi Government General Hospital & Madras Medical College,  
 Chennai-3 
I         have read the information in this form (or it has been read to 
me). I was free to ask any questions and they have been answered. I am over 18 years of age and, 
exercising my free power of choice, hereby give my consent  to be included as a participant in 
“Postoperative Troponin-T as a Marker of Myocardial Ischemic Injury in Mitral Valve Replacement 
Surgeries”. 
 
 
1.   I have read and understood this consent form and the information provided to me. 
2.   I have had the consent document explained to me. 
3.   I have been explained about the nature of the study. 
4.   I have been explained that 2ml of blood will be collected from me 24 hours after the 
surgery. 
5.   I have been explained about my rights and responsibilities by the investigator. 
6.   I have been informed the investigator of all the treatments I am taking or have taken in 
     the past 12 months including any native (alternative) treatment. 
 7.  I am aware of the fact that I can opt out of the study at any time without having to give any 
reason and this will not affect my future treatment in this hospital. * 
8.  I hereby give permission to the investigators to release the information obtained from me as 
result of participation in this study to the sponsors, regulatory authorities, Govt. agencies, 
and IEC. I understand that they are publicly presented.   
9.    I have understood that my identity will be kept confidential if my data are publicly presented. 
10.    I have had my questions answered to my satisfaction.  
11.  I have decided to be in the research study. 
12.  I have the right to refuse to give blood sample in case I don’t want to, for any reason. 
  
 
I am aware that if I have any question during this study, I should contact the investigator. By 
signing this consent form I attest that the information given in this document has been clearly 
explained to me and understood by me, I will be given a copy of this consent document. 
 
For Adult Participants: 
Name and signature / thumb impression of the participant (or legal representative if participant 
incompetent) 
 
Name     Signature   Date   
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Name and Signature of impartial witness (for illiterate patients): 
 
Name     Signature   Date   
 
 
 
Address and contact number of the impartial witness: 
 
 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name     Signature   Date   
 
For Children being enrolled in research:  
 
Whether child’s assent was asked: Yes / No (Tick one)  
[If the answer to be above question is yes, write the following phrase: You agree with the manner in 
which assent was asked for from your child and given by your child. You agree to have your child take 
part in this study].  
[If answer to the above question is’No’, give reason (s) :___________________________________.  
 
 
Although your child did not or could not give his or her assent, you agree to your child’s participation in 
this study.  
 
Name and Signature of / thumb impression of the participant’s parent(s) (or legal representative)  
 
Name   ________________________ 
Signature ________________________ 
Date  ________________________ 
 
Name   ________________________ 
Signature ________________________ 
Date  ________________________ 
 
 
Name and Signature of impartial witness (required for parents of participant child illiterate):  
 
Name   ________________________  
Signature _________________________ 
Date  _________________________ 
 
 
Address and contact number of the impartial witness:  
 
Name and Signature of the investigator or his representative obtaining consent :  
 
Name   __________________________ 
Signature __________________________ 
Date  __________________________ 
 
Signature of the principal investigator with date: 
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INTRODUCTION 
 Cardiac surgery is often complicated by some degree of myocardial ischemic 
damage, despite much improvement in myocardial protection strategies and surgical 
techniques. But, precise markers that can easily and specifically identify and quantify the 
extent of such damage is lacking. Electrocardiographic changes are of limited value in the 
perioperative period. Trans-esophageal echocardiography may be helpful in assessing left 
ventricular function and regional wall motion (which are indirect indicators of adequacy of 
myocardial protection) but it lacks the sensitivity to detect subtle degrees of myocardial 
damage. But, it is very essential to identify perioperative myocardial injury and its extent 
because it directly affects postoperative outcome. Further, the assessment of such injury is 
helpful to compare different methods of myocardial protection and will be useful in 
perioperative management of patients. 
 The development and availability of Troponin assays are considered to be one of the 
most important innovations in the past decade in cardiac diagnostics. Cardiac troponins 
(Troponin-T and Troponin-I) are proteins that are present in the thin filaments of myofibrils. 
They are released into the circulation whenever there is myocardial damage. Cardiac 
troponins are specific for cardiac muscle and are not expressed in skeletal muscle fibers. 
Due to their high sensitivity and specificity, they are appropriate markers for perioperative 
myocardial ischemic injury. 
 But several studies, which have plotted the kinetics of the Troponins, have shown 
that cardiac surgery per se, causes elevation of Troponin levels in the blood even when 
there is no evidence of myocardial ischemic damage. This is because of surgical trauma to 
the myocardium. The level of increase varies with different types of surgeries and with 
different lengths of incisions. It is difficult to define a cut-off value for Troponin levels 
which will indicate a perioperative MI in patients who have undergone CABG, because 
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Troponin is universally elevated in all patients who undergo cardiac surgery. This rise is 
due to both surgical trauma and myocardial ischemic injury. Thus, the significance of 
Troponin levels in post-cardiac surgery patients is still ill-defined. 
 However, we hypothesized that if high Troponin levels result in poor postoperative 
outcomes (e.g. increased duration of ventilation, duration of ICU stay, duration of inotropic 
requirement, cardiac failure, mortality, etc.) and vice versa, that would indicate that 
Troponin is a reliable marker for extent of myocardial “ischemic” damage because pure 
surgical trauma alone (which is same for any single type of surgery) is not going to have 
any influence on these postoperative outcomes. 
 
AIM OF THE STUDY 
Our prospective study was thus designed to analyse the correlation between 
postoperative outcomes and Troponin-T level and to find out if there is any positive 
correlation between Aortic cross clamp time and Troponin-T.  
If there is definite positive correlation between aortic cross clamp time and 
Troponin-T levels and between postoperative outcomes and Troponin-T levels, that 
becomes a definite evidence that this test is a viable and effective test in cardiac surgical 
field to assess the extent of myocardial ischemic injury. 
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REVIEW OF LITERATURE 
HISTORY OF EVOLUTION OF THE CONCEPT OF MYOCARDIAL 
PROTECTION 
Cardiac surgical procedures have been considered as unrealistic attempts even just 
100 years back. Billroth and Paget have viewed cardiac surgery with skepticism.  The first 
successful cardiac surgical procedure was the suturing of a stab wound in the right ventricle 
by Ludwig van Rehn in 1986. In 1902, Luther Hill performed a successful surgical 
procedure for a case of cardiac tamponade. These procedures, seemingly simple now, were 
performed one hundred years back as emergency resuscitative measures when cardiac 
surgery was unknown. 
Frederick Trendelenburg performed experimental pulmonary embolectomy in 
animals using “inflow occlusion” technique. Kirschner, a student of Trendelenburg, 
performed a successful pulmonary embolectomy in a human in 1924 using the same inflow 
occlusion technique. The need for myocardial protection was not known at that time. The 
inflow occlusion was used just to get a bloodless field. 
Alexis Carrel performed a descending aorta to coronary artery anastomosis in 1910 
in a dog. He was able to finish this anastomosis within 3 minutes of interruption of 
circulation. But, the fact that the heart fibrillated within these 3 minutes and the dog 
subsequently died after 2 hours, made him conclude that the anastomosis should be 
completed within 3 minutes and this important observation led to the knowledge that the 
heart cannot withstand ischemia under fibrillating conditions. 
Gibbon developed a cardiopulmonary bypass machine and started doing surgeries 
for congenital heart diseases in children. Due to repeated failures, he subsequently stopped 
using the machine. 
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Lillehei, using cross circulation, proved that heart surgeries could be feasible. CPB 
technology helped him perform successful surgeries and hence abandoned cross circulation 
after using it in 45 patients from 1954 to 1955.  
During the next few decades, the concept of global organ protection evolved with 
the use of hypothermia. In 1961, Hufnagel and colleagues introduced the concept of 
myocardial cooling by ice slush.  
Gradually, more complex cardiac surgeries were attempted. These procedures 
obviously needed longer periods of ischemia. Hence all these hearts suffered greater 
ischemic damage which was a great concern. Hypothermia was used to protect the heart 
from severe ischemic injury by lowering basal metabolic rate. But it did not provide a 
satisfactory protection for the heart. The concept of aortic cross-clamping was then applied. 
The heart stopped beating because of deprivation of high energy phosphate stores due to 
absence of blood supply. The cross-clamping technique greatly facilitated the surgery but at 
the same time making the heart prone to greater ischemic injury. 
At this time, Melrose described that the heart could be arrested by chemical 
technique rather than by ischemic technique. He used potassium citrate to chemically arrest 
the heart and postulated that this preserves high energy phosphates in the heart and hence it 
is safe. But contrary to his expectations, this technique did not provide adequate myocardial 
protection and was in fact abandoned in many centers. Topical hypothermia was then added 
as an adjunct to this form of cardioplegia for better cardiac protection. In St. Thomas 
Hospital in London, Hearse et al. developed a solution, which provided reliable cardiac 
arrest and good myocardial protection.1 
Gay and Ebert refined cardioplegia formulations in 1970s and 1980s. Follett and 
Buckberg described various strategies of cardioplegia delivery (temperature of cardioplegia 
solution, various routes of administration, etc). Buckberg found that blood was very useful 
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as a medium for cardioplegia administration. The composition of cardioplegic solutions 
continue to be modified worldwide according to various study reports proving superiority of 
one over another. 
 In 1978, Buckberg showed the importance of use of hyperkalemic reperfusate 
initially before aortic cross clamp is released.2        
DAMAGE FROM MYOCARDIAL ISCHEMIA 
Functional impairment of cardiac muscle in the absence of muscle necrosis is called 
myocardial stunning. This is usually a reversible phenomenon though it may last for few 
minutes to few days. 
Myocardial cell necrosis occurs when the ischemic process is prolonged though the 
time duration beyond which necrosis of muscle fibers starts has not yet been defined. The 
extent of myocardial cell necrosis is strongly influenced by various myocardial protection 
strategies. 
Contracture develops in cardiac muscle when ATP levels become critically low. 
This phenomenon is demonstrable in animals but uncommon in humans probably because 
the time to contracture is quite long in humans. The stone heart phenomenon usually starts 
in basal region of left ventricle and in subendocardium. 
DAMAGE FROM REPERFUSION 
Reperfusion damage to the myocardium is due to uncontrolled reperfusion i.e. 
reperfusion by unmodified blood and without control of flow or pressure.2 
The mechanism of reperfusion injury involves free oxygen radicals and calcium 
influx into myocytes.  
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The event of myocardial damage sustained due to ischemia cannot be separated from 
that due to reperfusion injury because both are interdependent. But the surgeon has the 
unique opportunity to control these two events separately. 
As the duration of ischemia prolongs, the myocardium undergoes the stage of 
myocardial stunning initially, and then myocardial necrosis. If ischemic process continues, 
stone heart develops, which usually indicates irreversible myocardial damage. This same 
course of events apply to reperfusion injury also. 
In any one heart, different areas of myocardium may be different stages of ischemic 
injury. Usually patchy areas of necrosis are interspersed among normal areas of viable 
myocardium. 
Microscopically, both apoptosis (programmed cell death without inflammation) and 
cell necrosis (cell death associated with inflammation) occur in post-cardiac surgical 
patients. Markus Malmberg, has demonstrated in animal studies that more the cardiac 
ischemic time more the degree apoptosis in cardiac muscle and also that ischemic 
preconditioning reduces the degree of apoptosis for any given duration of ischemic time. 
 
VULNERABILITY OF THE DISEASED HEART 
 Hypertrophied heart is more susceptible to ischemic and reperfusion injury than a 
normal sized heart. 
Chronic heart failure makes the heart more vulnerable to ischemic damage due to its 
already energy depleted state.  
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SURGICAL REQUIREMENTS 
Cardiac operations can be performed when the heart is beating and it is being 
perfused or during induced ventricular fibrillation, but a precise and complete intracardiac 
surgical procedure requires a quiescent heart and a bloodless field. This would also prevent 
systemic air embolism. Hence aortic cross clamping becomes a necessity for most cardiac 
operations. So, myocardial protection becomes mandatory in order to prevent ischemic 
myocardial damage. Cardiac activity should be immediately stopped to prevent depletion of 
high energy phosphate stores. This is accomplished by chemical cardiac arrest by 
cardioplegic solution containing potassium. 
  Since aortic cross clamping and cardioplegic arrest of the heart are routine 
procedures in open heart surgeries and during aortic cross clamping the heart is deprived of 
its blood supply through coronaries, various standardized myocardial strategies have 
evolved over time to avoid ischemic damage to the myocardium during this period of 
myocardial ischemia.  Some of them are projected to be superior to other techniques by 
various studies. But cardioplegic arrest of the heart is the gold standard against which others 
may be compared. 
CARDIOPLEGIA DELIVERY METHODS 
The goal of any technique of cardioplegia administration is to have uniform 
distribution of the solution to entire myocardium thus ensuring good myocardial protection. 
However, there is no single technique that is “best” for all circumstances. A practical 
knowledge of all the available techniques will help in special situations where other modes 
of cardioplegia delivery will be more useful than the conventional one in providing 
optimum protection to the myocardium. 
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Antegrade cardioplegia: 
In this technique, the cardioplegia is administered through aortic root, coronary ostia 
or bypass conduits after completing distal anastomosis in CABG. 
Most of the centers worldwide use the antegrade technique where cardioplegia is 
infused through aortic root because the technique is simple and efficient. It mimics the 
natural way of blood flow through coronaries. This method is not suitable in cases of aortic 
regurgitation or dissection in which aortotomy is done and the solution is administered 
through coronary ostia. Lifting or retraction of the heart (e.g. in Mitral valve surgeries) 
distorts the aortic valve and hence the heart must be repositioned before administering 
cardioplegia through aortic root. 
Intermittent and continuous cardioplegia: 
Continuous cardioplegia provides better myocardial protection but it is difficult to 
have a bloodless field in this technique and it also complicates the surgical field due to 
additional cannulae. 
Retrograde cardioplegia: 
It is helpful in patients with significant coronary artery stenoses where antegrade 
cardioplegia alone may not result in adequate distribution to entire myocardium. In this 
method, cardioplegia can be administered without interrupting the conduct of surgery. It is 
also useful for de-airing the coronaries and aortic root. 
The right ventricle and posterior aspects of the septum are not adequately perfused 
by cardioplegic solution in this method due to proximity of their draining veins to the 
coronary sinus ostium. 
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It is also important to limit the retrograde pressure from 25 to 35 mmHg. Pressures 
of more than 50 mmHg will produce myocardial edema and hemorrhage. 
Combined antegrade and retrograde cardioplegia: 
This method provides the opportunity to gain optimum benefits of both antegrade 
and retrograde cardioplegias in a single patient. 
Various compositions of cardioplegia solutions: 
Basically two different types of solutions are described: 
1. Extracellular or St. Thomas solution type 
2. Intracellular or Breschneider solution type. 
Extracellular solutions contain high sodium and calcium content with added magnesium. 
Intracellular solutions contain low sodium and calcium concentrations. Of these two types, 
the extracellular type is the most commonly used cardioplegia solution worldwide though 
some centers still continue to use intracellular type. 
Each of these subtypes has been modified in their compositions and concentrations by 
different manufacturers. 
Crystalloid and blood cardioplegia: 
Crystalloid cardioplegia is simple, cheap and easy to prepare and administer. Blood 
cardioplegia provides the following benefits: 
1. Ability to carry oxygen 
2. Excellent buffering capacity 
3. Scavenges free oxygen radicals 
4. Electrolyte and osmotic compositions are similar to blood 
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Temperature of cardioplegia solution: 
Cold cardioplegia (administered at 4 degree Celsius) is believed to provide better 
myocardial protection than warm cardioplegia (administered at 34-35 degree Celsius) 
though some studies have proved both of them to be equally effective. Tepid cardioplegia 
(28 degree Celcius) may provide advantages of both cold and warm solutions. 
 Additives in cardioplegia: 
Since the potassium used in the cardioplegia is injurious to coronary vascular 
endothelium, additives are being tried which may reduce the dose of potassium to produce 
cardiac arrest. 
 Nicorandil, an ATP sensitive potassium channel opener, is one such agent used to 
reduce the dose of potassium in cardioplegia solution. This drug also prevents perioperative 
coronary spasm. It has also been proved to precondition the heart against subsequent 
ischemic injury. 
L-arginine acts as a nitric oxide donor and helps in preventing endothelial 
dysfunction in ischemia-reperfusion injury. Its addition in cardioplegia solution has been 
shown to reduce postoperative Troponin-T release.1 
ADDITIONAL STRATEGIES OF MYOCARDIAL PROTECTION: 
Volatile anesthetic agents: 
Volatile anesthetic agents (Isoflurane, Sevoflurane) have been proved to enhance 
myocardial protection by poorly understood complex and multifactorial mechanisms. They 
ameliorate the deleterious effects of free oxygen radicals in the phase of ischemia-
reperfusion. In addition, they modulate potassium dependent ATP channels and produces 
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preconditioning effect. It has been shown that postoperative Troponin-T release is reduced 
with their use in anesthesia. Postoperative left ventricular function also is improved. 
 
Acute Normovolemic Hemodilution (ANH): 
This technique helps in better myocardial protection in two ways. First, it reduces 
requirement of blood transfusion. Secondly, it improves the rheologic characteristics of the 
blood and a reduction in hematocrit results in lower viscosity. This enhances myocardial 
blood flow to underserved areas of the myocardium.  
Neutrophil depletion: 
Neutrophils are associated with reperfusion injury by its release of destructive 
enzymes, free oxygen radicals and other toxic substances. Neutrophil depletion, either in 
CPB circuit or in cardioplegia solution has been shown to improve postoperative 
myocardial performance. Postoperative Troponin-T is also less in these patients. 
Other medications useful in myocardial protection: 
Erythropoietin, N-acetylcysteine, Desferoxamine and Statins have also been proved 
to enhance myocardial protection in some studies.1 
ISCHEMIC PRECONDITIONING: 
It is a phenomenon in which a previous sublethal ischemia to the myocardium 
provides protection against subsequent ischemic insults. In a study conducted by Ghosh et 
al. postoperative release of Troponin-T was less in those patients in whom ischemic 
preconditioning was applied. 
 
12 
 
FIBRILLATION: 
It is a useful, but less often used, strategy for myocardial protection. It relies on the 
principle of ischemic preconditioning. It is particularly useful in reoperative CABG 
surgeries where dissection and isolation of previous grafts and delivery of cardioplegia 
through them is difficult. 
WHAT IS TROPONIN-T: 
Troponin-T was discovered by Hugo A. Katus, a German physician. He 
subsequently developed a method to assay Troponin-T level. 
The cardiac muscle is made up of myocyte composed of bundles of myofibrils 
which contain myofilaments. These myofibrils in turn are made up of repeating units of 
sarcomere. These sarcomeres are the basic contractile units of cardiac muscle. Each 
sarcomere is defined on either side by z lines. The sarcomere contains actin (thin filament) 
and myosin (thick filament). The interaction between actin and myosin and their sliding of 
one over another causes contraction and relaxation of cardiac muscle. Myosin has ATPase 
that hydrolyses ATP to provide energy for actin-myosin bridge formation. Thin filament is 
made up of three types of proteins:  actin, troponin and tropomyosin. Actin is globular 
shaped protein arranged around rod shaped tropomyosin. Troponin proteins are attached to 
tropomyosin at regular intervals. 3 types of troponin proteins: Troponin-T, Troponin-C& 
Troponin-I (each coded by a separate gene). Troponin-T is attached to tropomyosin and 
troponin-C (which in turn is attached to Troponin-T) is the site for Calcium binding. During 
excitation-contraction coupling, calcium channels on sarcoplasmic reticulum open and 
calcium is released into sarcoplasm. These calcium ions bind to Troponin-C and bring about 
conformational changes in Troponin-T causing actin-myosin overlap. Troponin-I inhibits 
ATPase activity and thus inhibits the binding of actin and myosin and this inhibition is 
reversed by calcium attachment to Troponin-C.3 
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There are three tissue-specific subtypes of Troponin-T: 
T1 in slow skeletal muscle fibers 
T2 in cardiac muscle fibers (cTnT) and 
T3 in fast skeletal muscle fibers.4 
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The clinical laboratories use assays to detect cTnT (cardiac Troponin-T). Hence, its 
detection is specific for cardiac origin. Specificity to cardiac origin is close to 98%. Current 
methods of cardiac Troponin-T assay have only 2% cross-reactivity to skeletal Troponin.  
MECHANISM OF TROPONIN-T RELEASE DURING ISCHEMIC 
EVENTS: 
Myocardial ischemic injury, either reversible or irreversible, causes increased 
permeability of myofibrils and thus Troponin complexes are released into circulation. Thus 
Troponin-T or Troponin-I assessment in blood indirectly detects myocardial ischemic 
damage. 
Troponin is bound mainly to myofibrils (94%) and the rest 6% is cytosolic. When 
myocardial injury occurs, there is rapid early release of cytosolic Troponin-T and late 
gradual prolonged release from myofibrils. This affects the kinetics of Troponin-T release 
(Biphasic release pattern). The dissociation of that major portion that is compartmented in 
myofibrils is a time-consuming process and hence its long-lasting release. Though the 
serum half-life of Troponin-T is 120 minutes, this late and slow release of Troponin-T into 
the circulation is the reason for its values to remain high for upto 7-14 days.5 
Myocardial depressive factors that are released in the setting of inflammatory states 
(e.g. sepsis, CPB) cause degradation of Troponin molecules into smaller molecules which 
escape into the circulation because of increased membrane permeability. 7  
ELIMINATION OF TROPONIN-T FROM BODY: 
The exact mechanism of Troponin-T elimination from the body is unknown. It has 
been postulated that they are cleared by reticuloendothelial system (given the large size of 
these molecules). These large molecules are fragmented into small molecules and are 
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subsequently excreted by the kidney. A portion of them are also degraded by vascular 
endothelium.8 
CAUSES OF ELEVATION OF TROPONIN-T IN CARDIAC 
SURGERY: 
1. Direct surgical trauma, 
2. Inadequate myocardial protection,  
3. Reperfusion injury, 
4. Myocardial infarction and  
5. Cardioversion-defibrillation shocks 
Other causes of elevations of Troponin-T 7: 
1. Acute pulmonary embolism 
2. Acute pericarditis 
3. Acute of severe heart failure 
4. Sepsis and/or shock 
5. Myocarditis 
6. Hypertrophic cardiomyopathy 
7. Type A aortic dissection 
8. Strenuous exercise 
9. Renal failure 
10. Cardiac contusion after blunt chest wall trauma, external cardiac massage 
11. False positive troponin- Heterophilic antibodies, Rheumatoid factor, Fibrin clots, 
Microparticles,  Analyser malfunction 
There are four different theories that explain the persistent basal elevation of Troponin-
T in patients with chronic kidney disease and skeletal muscle disease.8 
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1. Theory of re-expression: in above said disease conditions, the cTnT re-expression 
occurs (a remembrance of early fetal form of expression)20  
2. Theory of cross-reactivity: the skeletal form of Troponin-T cross-reacts with cTnT 
in the first generation assay methods. However, this is avoided in second generation 
assays where more specific antibodies are used. 
3. Theory of isoforms: minimal amounts of isoforms of cTnT are expressed in skeletal 
muscles as well. 
4.  The kidneys have a role in clearance of Troponin-T from the body.21  
TROPONIN-T IN CARDIAC EVALUATION: 
The amino acid sequences of cardiac and skeletal forms of Troponin-T and I are 
different significantly and hence these two assays are useful in cardiac evaluation. But the 
structures of Troponin-C of both cardiac and skeletal muscle fibers are similar and so the 
assay of Troponin-C is not useful clinically. 
ESC/ACC committee has documented that any degree of myocardial necrosis will 
impair the clinical course of the patient and that there is no threshold value of elevated 
Troponin-T below which it can be considered harmless.  
It has been proved that even less than 1 gm of myocardial necrosis is detected by 
Troponin-T assay.7  
SENSITIVITY OF TROPONIN-T:  
Troponin-T is 95% sensitive for cardiac ischemic necrosis as it detects even subclinical 
levels of myocardial ischemic events (“microinfarcts”), which are not evident on ECG or 
ECHO findings. 
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SPECIFICITY OF TROPONIN-T: 
 With current methods of Troponin-T assay (2nd generation assays), the specificity of 
Troponin-T to cardiac origin is close to 98%.11 
PATTERN OF ELEVATION OF TROPONIN-T: 
Troponin-T level in blood starts to rise after 3-4 hours and peaks at 18-24 hours and lasts 
for 7-14 days in blood.10 
PREVIOUS STUDY RESULTS: 
Several studies have been conducted in the past in various parts of the world in 
similar manner as this study) to find out the significance of postoperative Troponin-T 
elevation.12 Most of such studies have demonstrated positive correlation between higher 
Troponin-T values and increased postoperative morbidity and mortality. These studies have 
also derived a cut-off value for Troponin-T levels in post-cardiac surgery patients beyond 
which the morbidity and mortality is increased. 
Most of such studies have been done on patients undergoing CABG. But, since 
adequacy of revascularisation and perioperative MI are major determinants of Troponin-T 
elevation in these kinds of patients, we didn’t want to conduct a study on patients 
undergoing CABG surgery (because this study is aimed to find out whether Troponin-T in 
postoperative period reflects the inadequacy of myocardial protection). If, in this study, we 
had included CABG surgeries also, perioperative MI would have been a major confounding 
bias. Also, those patients who have evidence of significant Coronary Artery Disease were 
excluded from the study by conducting Coronary Angiogram in patients over 40 years of 
age. Those with ECG evidence of CAD were also excluded from the study. 
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Some other studies have been undertaken with similar intent, but by including 
various kinds of cardiac surgeries in a single study. Various kinds of cardiac incisions in 
various parts of the heart and various lengths of incisions cause various levels of elevation 
of Troponin-T. Atrial incisions cause lesser level of Troponin-T elevation when compared 
to incision on ventricular muscle. Hence, mitral valve replacement surgery (MVR) alone 
was taken for this study, by which we have avoided an important bias. 
Sigismond Lasocki, analysed 502 consecutive patients who underwent various 
cardiac surgical procedures, and found that high Troponin-T value is an independent risk 
factor for postoperative mortality.13 
Hugo A katus et al, performed a study on 338 patients and showed that Troponin-T 
improves the efficiency in diagnosis of myocardial ischemia when compared to CK-MB. 
(sensitivity of Troponin-T was 94% and that of CK-MB 63%)13 
 Bernard L Croal, conducted a study in 1365 patients and showed that elevated levels 
of Troponin-T at 24 hours after surgery was associated with increased short-term, mid-term 
as well as long-term mortality.14  
James L Januzzi conducted a study on 224 patients to find out the significance of 
CK-MB and Troponin-T in post cardiac surgery patients. He found that elevated Troponin-
T level correlated well with post operative complications whereas the correlation of CK-MB 
was poor.15 
Joost Swaanenburg conducted a study on 123 patients undergoing various cardiac 
surgeries and found that when cross clamp time extends beyond 1 hour, there is rapid rise in 
Troponin-T levels. He also demonstrated that Troponin-T elevation levels depend on the 
type of cardiac surgery. Off-pump CABG surgeries did not cause a significant rise in 
Troponin-T level whereas on-pump CABG and valve surgeries produced Troponin-T 
elevation. Of all kinds of surgeries, valve surgeries produced highest levels of Troponin-T.15  
19 
 
H A Katus et al conducted a study in 56 patients and found that Troponin-T level 
raises correspondingly with cross clamp time.16  
Russel Hirsch et al, conducted a study on 56 pediatric patients and found that 
Troponin-T at 1 hour after surgery indicates the extent of myocardial damage and was 
predictive of difficult recovery.17  
Steven E. Lipshultz et al, conducted a study on 51 pediatric patients and showed that 
elevated Troponin-T levels are predictive of myocardial damage and its level correlates with 
increased morbidity and mortality.18  
Luc Jacquet et al, conducted a study on 117 patients and found that Troponin-T 
estimation after CABG was helpful to detect perioperative ischemia or MI and was superior 
to ECG findings in detecting early and mild ischemia.19  
OTHER METHODS ASSESSMENT OF ADEQUACY OF 
MYOCARDIAL PROTECTION: 
Adequacy of myocardial protection cannot be assessed directly but can only be 
assessed by indirect methods like ECG, Echocardiogram and by various factors that are 
influenced by myocardial protection. 
ECG:  
Though postoperative ECG may detect a significant myocardial ischemic injury by 
ST-T changes, minimal global ischemic injury is not always sufficient enough to cause such 
changes in ECG. Patchy distribution of areas of necrosis and partially viable myocardium 
amidst normal areas of myocardium is common after prolonged ischemic time. 
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ECHO: 
Regional wall motion abnormality may be detected by transthoracic ECHO (TTE) 
or, more accurately, by trans-oesophageal ECHO (TEE). But this finding occurs only in 
severely damaged myocardium. Ejection fraction in the postoperative period, when 
compared to preoperative status, may provide a clue to significant ischemic damage, though 
it may be influenced by various other factors like inotropic supports, volume status, residual 
anatomic lesion, patient-prosthesis mismatch, fever, sepsis, etc. 
Functional status: 
NYHA classification of functional status is a good tool to compare pre and 
postoperative status. But the classification is based on one’s own subjective feeling of 
wellness and it is not sensitive and specific enough to detect minor or even moderate 
degrees of myocardial ischemic injury. A poor NYHA status postoperatively may be due to 
not only cardiac function impairment but also pulmonary functional status, renal function, 
skeletal muscle system, central nervous system, liver function, hemoglobin level, nutritional 
status, psychological motivation, etc. 
Mortality rate: 
Severe myocardial ischemic injury may be a cause of or sometimes a precipitating 
factor for postoperative mortality. In studies involving large number of patients, it may be 
found that Troponin-T elevation is a risk factor for postoperative death occurring within 1 
month. But, since the mortality rates of open heart surgeries are generally very low in most 
of the cardiac surgical centers, the use of mortality rate, as an indicator of poor myocardial 
protection, is difficult in small scale studies. 
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CK-MB:  
Since these enzymes are found in skeletal muscle as well, the assay of CK-MB is not 
sufficiently specific for cardiac origin. CK-MB used to be the commonly used cardiac 
marker earlier, till the arrival of Troponin-T assay. This test was widely used by 
cardiologists in acute coronary syndromes before the advent of Troponin-T. Since 
Troponin-T assay is now available in most of the hospitals, the use of CK-MB has come 
down.15 
CK-MB is not specific to cardiac muscle because there is significant overlap 
between cardiac and skeletal muscle CK structure. Hence CK-MB assay is not as reliable as 
Troponin-T for assessing extent of myocardial ischemic injury. 
It has been proved in studies that even with a transient myocardial ischemia which 
causes “reversible” myocardial damage, Troponin-T is released into circulation. This proves 
the high sensitivity of Troponin-T assay in detecting myocardial injury.7  
INTRA-OPERATIVE MONITORING OF MYOCARDIAL 
PROTECTION: 
These are the techniques used to monitor both adequacy and uniform distribution of 
cardioplegia. Myocardial temperature and pH monitoring are the two mainstays of intra-
operative monitoring of adequacy of myocardial protection.1 
Myocardial Temperature monitoring: 
Thermocouple needles inserted into the myocardium is the most commonly used 
technique. Usually a single needle is inserted into the septum and the temperature is 
monitored. The adequacy of cardioplegia solution is dictated by the temperature attained at 
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the septum. When rewarming of the septum occurs, it becomes an indication for repeat 
cardioplegia. 
Myocardial pH monitoring: 
pH monitoring is not used widely but it is a useful tool to monitor adequacy of 
myocardial protection. pH monitoring can be done either directly by small pH meters 
inserted through the myocardium or indirectly through measurement of pH in coronary 
sinus effluent. 
Research level assessment of adequacy of myocardial protection: 
For experimental purposes, myocardial biopsy can be taken from animals that are 
subjected to aortic cross clamping either by transvenous route when the animal is alive or 
by postmortem studies when the animal is sacrificed. In humans, postmortem biopsies of 
myocardium may be examined for patchy muscle necrosis, myofibrillar degeneration, etc.  
for research purposes. 
IMPORTANCE OF OUR STUDY: 
Since poor myocardial protection and the injury sustained due to ischemia-
reperfusion injury has its effects in both immediate postoperative period (unstable 
postoperative period, prolonged ventilator support, increased inotropic support, prolonged 
ICU stay, increased mortality rate) as well as in long term results (poor functional class, 
poor LV function, early mortality), its avoidance will result in overall improvement in 
patient’s postoperative status and also a reduction in mortality. The identification of 
presence of myocardial ischemic injury and its extent in every individual patient will help to 
self-evaluate the techniques we follow in myocardial protection. If there is a single test 
which detects both the presence and the severity of myocardial injury specifically and with 
100% sensitivity, that test can be used to evaluate all patients postoperatively both to find 
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out the cause of poor hemodynamic status as well as for research purposes to evaluate the 
efficacy of different methods of myocardial protection and different kinds of cardioplegic 
solutions.  
Of all the tests available so far in this category, only Troponin-T evaluation has 
highest sensitivity and specificity.9 But the important factor of surgical myocardial injury 
complicates the practical use of this test. Any surgical incision on the heart causes release of 
Troponin-T into the circulation and hence Troponin-T elevation is universal after any 
cardiac surgery. It is important to differentiate Troponin-T elevation due to ischemic 
damage from that due to surgical incision. Many scientific papers have been published 
about the significance of Troponin-T values in postoperative period. These papers have 
proved a fact that the rise of Troponin-T in postoperative period follows a predictable 
pattern i.e. the initial rise upto a certain level can be considered to correspond to surgical 
injury and later phases of elevation beyond this level indicates the level of myocardial 
ischemia-reperfusion injury. 
The significance of Troponin-T after cardiac surgery still remains undefined. 
This study that we have undertaken is another attempt to find out if the Troponin-T 
level predicts the severity of ischemic injury differentiating it from surgical injury based on 
a cut-off value between the two. In other words, our aim was to find out if Troponin-T 
elevation in post-cardiac surgery patients is predictable or is erratic without any 
predictability. (by the word “predictable”, we mean “predictable level of troponin-T 
consistent with the severity of ischemic myocardial injury”) 
USEFULNESS OF TROPONIN-T IN CARDIAC SURGICAL 
PATIENTS: 
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Troponin-T should be routinely used after open heart surgeries for following 
reasons:  
1. The value of Troponin-T in a postoperative patient tells us about the efficacy of 
myocardial protection strategies applied in that patient and to review any deficiencies in 
myocardial protection. In a long term basis, this would help improve the myocardial 
protection strategies that we follow in our hospital. 
2. This test is useful to find out the cause of difficult postoperative period in some 
patients (unexplained postoperative hemodynamic instability). 
3. Identification of high risk patients by high Troponin-T values may direct us to 
take special care in these individuals so as avoid morbidity or mortality. More duration of 
intensive care monitoring, special interventions and efficient use of economic resources 
may be directed to these high risk patients. By these measures, the patient outcome may be 
improved. 
THE NORMAL CUT-OFF VALUES FOR TROPONIN-T: 
The cut-off values for Troponin-T for detecting acute cardiac ischemic events (non-
surgical) are well known but these values are not applicable for cardiac postoperative status 
because Troponin-T levels are invariably elevated in all patients undergoing cardiac 
surgery, irrespective of the complexity of surgery. Hence we need to find out the cut-off 
value for Troponin-T in post cardiac surgery status (specifically for each type of cardiac 
surgery). Below this cut-off level, the values would indicate incisional elevation and beyond 
this, would indicate ischemic necrosis. 
 The standard textbook in cardiology, Hurst’s The Heart, denotes the normal and 
abnormal values for Troponin-T as below: 
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 upto 0.01ng/ml (normal) 
 Upto 0.09 (borderline) 
>0.1 (Indicative of myocardial infarction). 
But, these values are not applicable to patients who have undergone cardiac surgery 
as the postoperative values of Troponin-T are usually much exceeded than 0.1ng/ml. Hence, 
new cut-off values should be derived for cardiac surgical patients, (more specifically, cut-
off values for each type of cardiac surgery). Many previous studies have found that when 
the levels go beyond 13ng/dl, the mortality rate goes steeply high. 
TROPONIN-T ASSAY METHOD: 
Troponin-T in blood is assessed by immunometric one-step sandwich technique. 
The testing is based on polyclonal antibodies specifically developed against epitopes on 
cTnT molecule. These epitopes differ significantly between cardiac Troponins (cTnT) and 
skeletal Troponins. 
 In this method, polyclonal antibody to epitopes of cardiac Troponin-T is 
immobilized in polyvinylchloride test tubes. Troponin-T standards (control) or serum 
samples and peroxidase-labeled anti-Troponin-T monoclonal antibody is added to these test 
tubes. When incubated, Troponin-T molecules are adsorbed onto polyclonal antibody 
(which are in solid-phase) and to monoclonal antibody-enzyme complex (which are in 
liquid phase). The unbound peroxidase-labeled monoclonal antibodies are removed by 
washing. Now, the antibody-enzyme complexes which are adhered to the tubes correspond 
to Troponin-T level in that patient. The amount of enzyme immobilized is the direct 
measure of bound Troponin-T and this is measured by spectrophotometer (by peroxidase 
substrate conversion at 405 nm wavelength).13  
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DETAILS OF THE STUDY 
The study was intended to find out if Troponin-T assay in postoperative status was 
useful as an indicator of myocardial ischemic injury sustained during aortic cross clamp and 
cardioplegic arrest. 
To analyse the correlation between myocardial ischemic injury and Troponin-T level, 
we decided to correlate the following variables with the level of Troponin-T. 
1. Aortic cross clamp time 
2. CPB time 
3. CP interval time 
4. Longest Time Off Cardioplegia (LTOC) 
5. Average Time between each cardioplegia (ATOC) 
6. Postoperative duration of ventilation 
7. Duration of ICU stay 
8. Inotropic support required 
9. Post op ECG evidence of myocardial ischemia 
10. ECHO evidence of myocardial ischemia 
11. Clinical evidence of failure (evidence of pulmonary edema, requirement of excess 
diuretics, etc) 
12. Postoperative functional status(NYHA) 
13. Mortality  
The mortality rate following open heart surgeries are too low to be used as a marker of 
poor surgical results in a small scale study. Hence, we depend on other evidences of 
myocardial injury to establish correlation between poor myocardial protection and poor 
postoperative outcomes. 
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EXCLUSION CRITERIA: 
Those patients with severely depressed cardiac function (EF<40%) require special 
care during myocardial protection measures. And also there is a rise in Troponin-T level in 
blood of patients in failure. Hence these patients were excluded from the study. 
As already mentioned, those patients who have evidence of coronary artery disease 
(ECG or Echo evidence) were excluded from the study since perioperative MI may cause a 
rise in Troponin-T elevation. Patients older than 40 years are routinely evaluated with 
coronary angiogram and those who have significant coronary artery disease are also 
excluded from the study. 
Patients who had already undergone Closed Mitral Commissurotomy (CMC) and 
now undergoing mitral valve replacement surgery were excluded, as during dissection of 
adhesions, direct surgical injury to myocardial tissue occurs. 
Patients with more than mild AR were also excluded. 
Since Troponin-T elevation occurs in patients with chronic renal failure due to 
unknown reasons (explained below), CKD patients were excluded from the study. 
Patients with elevated liver function tests were also excluded since the excretion of 
Troponin-T may be affected in these patients.7  
THE TIMING OF THE TROPONIN-T ESTIMATION IN THIS STUDY: 
Since Troponin-T levels usually reach their peak values at around 18-24 hours after an 
ischemic event, and then start to decline, a single estimation of its value at 24 hours is used 
in this study. Most of the previous studies to evaluate the correlation of Troponin-T with 
myocardial ischemic time have used this same kind of testing (i.e. a single measurement at 
24 hours after surgery, though some of the studies have done Troponin-T assay at 20 hours) 
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It has been proved in studies that even with a transient myocardial ischemia which causes 
“reversible” myocardial damage, Troponin-T is released into circulation. This proves the 
high sensitivity of Troponin-T assay in detecting myocardial injury.7  
THE STANDARD STEPS OF A MITRAL VALVE REPLACEMENT 
SURGERY IN OUR HOSPITAL: 
Under General Anesthesia, median sternotomy is done. Thymus is mobilized. 
Pericardial cradle is created. Cardiopulmonary bypass is established with bicaval and aortic 
cannulae after heparinisation. Alpha-stat acid-base management protocol is followed. 
Heparin is administered at a dose of 300 U/kg body weight. Activated Clotting Time (ACT) 
is tested after 5 minutes and it is maintained above 480 sec throughout cardiopulmonary 
bypass. Priming solution (for an adult) is prepared by adding 500ml of Ringer-Lactate 
solution + 500ml of Hetastarch . 100ml of Inj.Mannitol (20%), 50 ml of Inj.Sodium 
Bicarbonate and 2ml of Inj.Dexamethasone are added to this solution. Heart is cooled to 32 
degree Celsius gradually over 5 minutes. Aorta is cross clamped at 32 degree C. Antegrade 
cardioplegia is administered through a 12 Fr cannula in the ascending aorta with digitally 
guided aortic root pressure, for a duration of 2-3 minutes. Cardioplegic solution is prepared 
with Inj.Plegiocard. 4:1 blood cardioplegia is prepared. This solution is administered at 4 
degree Celsius. The left atrium is opened to avoid distension of the left heart. After 
cardioplegia administration and electromechanical quiescence of the heart is obtained, ice 
slush is poured into pericardial cavity and its spread underneath the heart is ensured. 
Cardioplegia is repeated every 20-30 minutes or upon seeing the cardiac activity, depending 
on whichever is earlier. Ice slush is applied after every cardioplegia administration. When 
the surgery is predicted to be over within 10 minutes ice slush is avoided during the last 
cardioplegia. Core cooling is done upto 28 degree Celsius. Once left atrium is opened, any 
clot in the cavity or in LA appendage is removed. LA appendage exclusion is done, in 
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patients with LA/LA appendage clot, with circumferential sutures taken on endocardial side 
of LAA using 3-0 prolene. Anterior mitral leaflet (AML) and posterior mitral leaflet and 
subvalvular apparatus are examined. PML is fully or partially preserved if anatomy is 
favorable. AML and its chordate are removed. Intermittent horizontal mattress sutures are 
taken from atrial side (so that the pledgets lie on atrial side and the valve lies intra-
annularly) using 2-0 Ethibond pledgetted sutures with 13 mm round-bodied half circle 
needles. The valve sizer is used to measure the annulus size and valve is selected according 
to it. Selection of tilting disc or bileaflet valve depends on surgeon’s preference as well as 
the availability of valve at that time (valves being supplied by the TNMSC). All the suture 
needles are subsequently passed through the sewing ring of the prosthetic valve and the 
valve is parachuted to the annular position. The sutures are tied securely with 5 knots. After 
mitral valve implantation, the mobility of the prosthetic valve leaflet(s) is tested. Any 
subvalvular chordae or other structure interfering with the movement of the leaflet is cut 
away or else the valve is rotated within the sewing ring such that the mobility is 
unrestricted. Usually, a tilting disc valve is positioned with its larger orifice facing 
posteriorly if PML was excised and anteriorly if PML is preserved. A bileaflet valve is 
positioned in anti-anatomical position. Left atrium is closed in two layers using 3-0 prolene 
and before tying the last knot, the LA is de-aired. The CP cannula in ascending aorta is used 
for de-airing and blood is allowed to be ejected through this for 5 minutes and later it is 
connected to pump with 300ml/min reverse flow. Aortic cross clamp is removed with head 
end down and with carotid compression and with the pump flow reduced to 0.5 lit/min. This 
flow rate is gradually increased to normal flow over 2-3 minutes. Defibrillators are used 
when necessary. The heart is supported with pump for a duration of 1/3rd of total cross 
clamp time. Heart is weaned from cardiopulmonary bypass gradually. CP cannula, SVC and 
IVC cannulae are removed and Protamine infusion is started. When half of the protamine 
infusion is completed, aortic cannula is removed. Protamine dose is calculated according to 
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the total dose of heparin given during the surgery (1.2mg for 1mg of heparin) also 
considering the ACT value and the time interval between heparin administration and 
protaminisation. Intercostal and/or mediastinal drainage tubes are placed. After hemostasis, 
sternum is approximated with 6 metric steel wires (in an adult); subcutaneous layer 
approximated with 2-0 Vicryl and skin with subcuticular absorbable sutures. The inotropic 
support is started only when it is indicated according to the hemodynamic status and not on 
a regular basis. Postoperatively, patient is shifted to Intensive Care Unit where each patient 
is cared by a single nurse. 
CARDIOPLEGIC METHOD FOLLOWED IN OUR INSTITUTION: 
 Antegrade, intermittent, cold and blood cardioplegia is the routine cardioplegia 
method followed in our institution for all cases of Mitral Valve Replacement (MVR) 
surgeries. 4:1 blood cardiolplegia is administered at a dose of 20ml/kg for first time and 
then 10ml/kg subsequently. 
ANESTHESIA: 
Patients are given premedication and pre-operative antibiotics 30 minutes before 
surgery. Induction is done Inj.Thiopentone and Inj. Fentanyl is used as a narcotic. 
Inj.Vecuronium is used for paralysis. Inhalant anesthetic, Isoflurane is used at 1MAC. It has 
been proved in studies that Isoflurane has pre-conditioning effect on the heart and its use is 
associated with lower postoperative Troponin-T levels. 
POST-OPERATIVE CARE: 
 Patients are monitored in cardiothoracic ICU where each patient is monitored by a 
single nurse. The team leader of the ICU is a cardiothoracic surgeon. Inotropic supports are 
not a routine protocol in our hospital but are started only on the basis of hemodynamic 
status. Patients are extubated when they are hemodynamically stable, fully alert and there is 
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no significant post-operative bleeding. Some of the surgical units have a protocol to 
extubate them only on the 1st post-operative day in the morning hours. Intravenous 
unfractionated Heparin (5000 units) is administered 10 hours after surgery if there is no 
significant drain and Acinocoumerol is started in the evening of 1st postoperative day. 
Patients are monitored in this ICU for minimum 2 days after surgery. When patient is 
stable, patient is shifted to step-down ICU where each nurse monitors 5 patients.  
TROPONIN-T LEVEL ESTIMATION 
Troponin-T analysis was done when 24 hours had passed after surgery. For this 
purpose, 2ml of blood is collected from the patient and is sent to the lab in a test tube (The 
cost of the test was borne by the prinicipal investigator). The testing was done in a private 
lab (Hi-Tech Labs) and all the 51 samples were analysed in the same laboratory. The blood 
sample was centrifuged immediately and the serum was used for estimation of Troponin-T 
level by Electro-chemiluminescence (ECLIA) method. The results are given in ng/ml units. 
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MATERIALS AND METHODS 
This prospective study was undertaken as an analytical study to find out the 
significance of post-operative Troponin-T level as a marker of myocardial ischemic injury 
in mitral replacement surgeries, in cardiothoracic surgery department of Rajiv Gandhi 
Government General Hospital, Chennai-600003, from April 2012 to March 2013. Hospital 
Ethical Committee approved this study to be conducted in Rajiv Gandhi Govt General 
Hospital. Patients were well informed about the nature of the study and consent was 
obtained in written format for withdrawal of 2 ml of blood and Troponin-T estimation. 
INCLUSION CRITERIA 
 Patients who were to undergo Mitral Valve Replacement Surgeries during the above 
said period were included in the study. Both Rheumatic and Non-rheumatic pathologies 
were accepted for the study. Both stenotic (MS) and regurgitant (MR) lesions (or a 
combined of two) were included. Only patients aged more than 13 years were included in 
the study. 
EXCLUSION CRITERIA 
1. Patients who have evidence of coronary artery disease 
2. Re-do mitral valve surgeries (Post-CMC) 
3. Poor left ventricular function (EF<40%) 
4. LV diastolic dimension >7.0 cm 
5. Renal failure 
6. Hepatic failure 
7. Patients with more than mild AR (aortic regurgitation) 
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METHODOLOGY 
 The preoperative, per-operative and post-operative details were personally collected 
by the investigator by direct communication with the patient and by assisting during the 
surgery and also following-up the patient in post-operative period. The data regarding 
significant events after discharge of the patients were also traced by phone communication 
and by follow-up in the out-patient department. 
 The information and data collected for each patient were entered in the proforma 
specially designed for this study. 
 The following information/data were collected from each patient. 
1. Name, age, sex, IP number, Date of admission 
2. ECG and Echo findings- Echocardiogram is done both by cardiologists and 
cardiothoracic surgeons. 
3. Pre-operative functional class (NYHA classification was used) 
4. Presence or absence of Atrial fibrillation 
5. Total cross clamp time 
6. Number of times cardioplegia was administered 
7. Longest time off cardioplegia (Longest time between any two consequent 
cardioplegia) 
8. Average time interval of cardioplegia (time interval between consequent 
cardioplegia doses) 
9. Cardiopulmonary bypass (CPB) time 
10. Requirement of DC shocks: it has been proved in studies that, though external 
defibrillator application causes elevation of Troponin-T, internal cardioversion does 
not cause any such elevation. 
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11. Requirement of post-operative inotropic support. This was classified into three 
categories for the purpose of ease of calculation and better understanding. 
Drug Minimal Intermediate High 
Dopamine <5ug/kg/min 6-10ug/kg/min >11ug/kg/min 
Adrenaline <0.05ug/kg/min 0.06-0.1ug/kg/min >0.11ug/kg/min 
Isoprenaline <0.05ug/kg/min 0.06-0.1ug/kg/min >0.11ug/kg/min 
 
12. Duration of inotropic supports (in days) 
13. Duration of postoperative ventilation (in hours) 
14. Duration of ICU stay (in days) 
15. Duration of hospital stay after surgery (in days) 
16. ECG or echo evidence of myocardial ischemia. A new q wave of more than 0.1 mV, 
or ST-T changes in two consequent leads suggestive of ischemia were taken as 
positive evidences of perioperative MI or significant ischemic injury. ECG 
interpretation was done by cardiologists in association with cardiothoracic surgeons. 
Postoperative echo was performed by cardiologists in the immediate post-op period 
if patient is hemodynamically unstable but only after 7 days if patient is stable. 
17. Clinical evidence of failure: patient was examined by the investigator for presence 
of any signs of cardiac failure like, pulmonary crepitations, pedal edema, 
tachycardia, dyspnoea, mental obtundation, cold peripheries, high CVP, reduced 
urine output, etc., Patient’s symptoms were also taken into account.  
18. Ejection fraction of left ventricle: this was categorized into three varieties.  
EF 41-50% - mild dysfunction  
EF 31-40% - moderate dysfunction 
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EF <30% - severe dysfunction 
19. Postoperative NYHA status: patients were classified into 3 categories: those who got 
improved after surgery and those who didn’t get any improvement and those who 
got worsened after surgery. 
20. Requirement of IABP 
21. Mortality: the cause of mortality was assessed and was ascertained whether it is due 
to cardiac cause or non-cardiac cause. 
 
ANALYSIS METHODS 
Data were analysed with the help of a doctor specialized in statistics. 
Descriptive statistics: mean+ standard deviation was calculated. 
 Correlation for continuous variables was done. Chi-square/Fischer’s test was done 
for categorical variables. Independent  ‘t’ test was done to look for significant different 
between 2 groups. ROC (Receptor Operator Characteristic) curve was used to determine the 
cut-off level of troponin-T at which levels, the postoperative complications occur more. By 
ROC curve, the level was fixed at 0.6 ng/ml. 
Data was entered in Microsoft Excel Spreadsheet and was analysed using SPSS 
(Statistical Package for Social Science) version 16. 
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RESULTS 
AGE DISTRIBUTION: 
The Age group extended from 15 years to 61 years.  
Mean age was 32.92 + 12.02 years and median age was 32 years.  
 
SEX DISTRIBUTION: 
Among the study participants, 75 % were females 
 
 
LESION-WISE CLASSIFICATION: 
16 (31.4%) patients had mitral stenosis 
13 (25.5%) patients had mitral regurgitation 
22 (43.1%) patients had both mitral stenosis and regurgitation 
17 (33.3%) patients had pre-operative atrial fibrillation 
2  (3.9%) patients had LA clot. 
25 
75 
MALE
FEMALE
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NUMBER OF CP (NUMBER OF TIMES CARDIOPLEGIA WAS 
ADMINISTERED):  
1 – 1 (2%) 
2 – 30 (58.8%) 
3 – 18 (35.3%) 
4 – 2 (3.9%) 
Average: 2.4 
Median: 2 
For those patients, who received 1 or 2 cardioplegias, the average Troponin-T level was 
0.676 ng/ml. 
For those, who received 3 or 4 cardioplegias, the average troponin-T value was 0.706 ng/ml. 
 
 
TOTAL CROSS CLAMP TIME:  
Average: 68 + 2 minutes 
Median: 70 minutes 
Longest: 87 minutes 
Shortest: 28minutes 
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Aortic cross clamp time Number of patients % 
Average 
Troponin-T value 
for this group 
<70 minutes 27 52.9% 0.567 ng/ml 
> 70 minutes 24 47.1% 0.821 ng/ml 
Total 51 100% 
 
 
The above table shows that Troponin-T levels are elevated with increasing duration of 
aortic cross clamp time. 
 
LONGEST TIME OFF CARDIOPLEGIA (LONGEST INTERVAL 
BETWEEN CARDIOPLEGIAS IN A SINGLE PATIENT): 
Mean:    28 + 1 minutes 
Median:  28 minutes 
Longest:   38 minutes 
Shortest:  22 minutes 
Longest Time Off 
Cardioplegia 
Number of 
patients % 
Average 
Troponin-T value 
for this group 
< 28 minutes 29 56.8% 0.661 ng/ml 
>28 minutes 22 43.1% 0.723 ng/ml 
Total 51 100 
 
 
The above shows that when the interval between two cardioplegias is prolonged, Troponin-
T levels are simultaneously elevated. 
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AVERAGE TIME INTERVAL OF CARDIOPLEGIA: 
Mean:   26 + 1 minutes 
Median:  26 minutes 
Maximum :  34 minutes 
Minimum :   21 minutes 
Average interval 
between cardioplegias 
Number of 
patients % 
Average 
Troponin-T value 
for this group 
<  26 minutes 27 53% 0.594 ng/ml 
> 26minutes 24 47% 0.739 ng/ml 
Total 51 100% 
 
 
The above table shows that when the interval between two cardioplegias is prolonged, there 
is increased troponin-T release. 
Lichtenstein et al, has used these two parameters in his study, to assess the efficacy of 
intermittent warm blood cardioplegia. 
LTOC- Longest Time Off Cardioplegia (Longest single ischemic time in a patient) 
PTCO- Percentage Time Off Cardioplegia25 
 
CPB DURATION: 
Average CPB duration:  97 + 2 minutes 
Maximum : 140 minutes 
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Minimum : 57 minutes 
CPB duration Number of patients % 
Average 
Troponin-T value 
for this group 
<97 minutes 21 41.1% 0.658 ng/ml 
>97 minutes 30 58.8% 0.709 ng/ml 
total 51 100 
 
 
The above table shows that when CPB duration is increased, Troponin-T levels are 
elevated. 
 
REQUIREMENT OF INOTROPIC SUPPORTS: 
Inotropic support 
Number of 
patients 
% 
Average 
Troponin-T value 
for this group 
Nil 15 29.4 0.522 ng/ml 
Minimal / Intermediate 30 58.8 0.729 ng/ml 
High 6 11.8 0.894 ng/ml 
Total 51 100  
 
From the above table, it is evident that higher doses of inotropes are required in those 
patients whose Troponin- T values are high. 
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DURATION OF INOTROPIC AGENTS: 
 37 (72.5 %) patients required inotropic for < 2 days. Their average Troponin-T value was: 
0.59 ng/ml. 
14 (27.5) patients required inotropic support for more than 2 days. Their average Troponin-
T value was: 0.93 ng/ml. 
 
Duration of inotropic 
support 
Number of 
patients % 
Average 
Troponin-T value 
for this group 
<   2days 37 72.5% 0.59 ng/ml 
> 2 days 14 27.5% 0.93 ng/ml 
Total 51 100 
 
 
 
DURATION OF VENTILATION: 
44 (86.3%) patients required ventilation for less than 24 hours and their average Troponin-T 
value was: 0.61 ng/ml. 
7 (13.7%) patients required ventilation for more than 24 hours and their average Troponin-T 
value was: 1.17 ng/ml. 
Duration of ventilator 
support 
Number of 
patients % 
Average 
Troponin-T value 
for this group 
Less than 24 hours 44 86.3% 0.61 ng/ml 
More than 24 hours 7 13.7% 1.17 ng/ml 
Total   
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RELATIONSHIP BETWEEN DC SHOCK AND TROPONIN-T 
VALUES: 
9 patients received DC shock after cross clamp release for defibrillation. For those patients 
who received DC shocks, the average Troponin-T value was: 0.85 ng/ml. [Minimum: 0.32 
and Maximum: 1.90] 
42 patients did not receive DC shock.  For those who did not require DC shocks, the 
average Troponin-T value was: 0.65 ng/ml [Minimum: 0.12 and Maximum: 1.88] 
This data suggests that DC shock may be a cause for Troponin-T elevation. 
 
REQUIREMENT OF IABP: 
Only one patient required IABP support in the postoperative period and her Troponin-T 
value was  0.517 ng/ml. 
 
POST-OPERATIVE EVIDENCE OF FAILURE: 
 
 
Postop cardiac 
failure Number % 
Average 
troponin-T value 
for this group 
No 40 78.4 0.607 ng/ml 
Yes 11 21.6 0.981 ng/ml 
Total 51 100  
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40 patients had no evidence of cardiac ischemia/failure (ECG/ECHO/clinical) 
postoperatively and their average Troponin-T value was 0.607 ng/ml.  
11 patients had evidence of cardiac failure (ECG/ECHO/clinical) postoperatively and their 
average Troponin-T value was 0.981 ng/ml. 
 
ICU STAY: 
28 (54.9 %) patients had ICU stay of < 5 days. Their average Troponin-T value was 0.655 
ng/ml. 
23 (45.1 %) patients had ICU stay of > 5 days. Their average Troponin-T value was 0.727 
ng/ml. 
Mean ICU stay – 5.29 days 
Median ICU stay – 5 days 
(The average duration of ICU stay is notably high because it is our hospital policy to retain 
the patients in ICU for an average of 5 days) 
 
ICU stay Number of patients % 
Average 
Troponin-T level 
for this group 
< 5 days 28 54.9% 0.655 ng/ml 
> 5 days 23 45.1% 0.727 ng/ml 
Total 51 100 
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TOTAL HOSPITAL STAY AFTER SURGERY: 
24 (48.8 %) patients (excluding 2 deaths) had < 12 days of hospital stay. 
25 (51.2 %) patients had > 12 days of hospital stay. 
For patients who had less than 12 days of hospital stay, the average Troponin-T value was:  
0.51ng/ml . 
For patients, who had more than 12 days of hospital stay, average Troponin-T value was: 
0.82 ng/ml. 
Total hospital stay after 
surgery 
Number of 
patients % 
Average 
Troponin-T level 
for this group 
< 12 days 24 48.8% 0.510 ng/ml 
> 12 days 25 52.2% 0.820 ng/ml 
Total 49  
 
 
 
NYHA STATUS: 
 
Pre-op NYHA Frequency Percent 
 
II 5 9.8 
III 38 74.5 
IV 8 15.7 
Total 51 100.0 
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Post-op NYHA Frequency Percent 
 
I 17 33.3 
II 25 49.0 
III 7 13.7 
IV 2 3.9 
Total 51 100.0 
 
Postoperatively, 42 patients were in NYHA I/II. Their mean Troponin T value was 0.57 
ng/ml 
7  patients were in NYHA III/IV. Their mean Troponin T value was 1.26 ng/ml. 
NYHA 
(Post- OP) 
Frequency Percent Average Troponin-T for this group 
I&II 42 82.3% 0.57 ng/ml 
III&IV 9 17.6% 1.26 ng/ml 
 51 100%  
 
This table shows that when Troponin-T level is high, the patient is more likely to be in 
NYHA Class III or VI. 
 
MORTALITY:  
Only two patients died in our study population. Their Troponin-T values were 1.570 and 
0.80 ng/ml. 
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DESCRIPTIVE STATISTICS FOR THE VARIABLES: 
 
 
N 
Minimu
m 
Maximu
m Mean 
Std. 
Deviation 
Age 51 15 61 32.92 12.020 
Sex 51 1 2 1.75 .440 
Troponin T 51 .12 1.90 .6881 .41895 
Cross_cramp_time 51 28.00 87.00 68.0784 12.17020 
Cpb duration 51 57.00 140.00 97.5490 13.89146 
LTOC 51 22.00 38.00 28.0000 2.59230 
ATOC 51 21.00 34.00 25.9804 2.59608 
No_of_CPs 51 1.00 4.00 2.4118 .60585 
Duration_of_postop__s
upports 
51 .00 6.00 1.9608 1.79956 
Duration_of_ventilation 51 4.00 120.00 23.8235 24.98536 
Postop_EF 51 40.00 84.00 62.9216 14.17581 
ICU_stay 51 3.00 12.00 5.2941 2.44372 
Total_hospital_stay_aft
er_surgery 
51 7.00 30.00 12.7843 4.80963 
  
    
 
 
 
 
 
 
 
47 
 
 
 
 
 
 
y = 11.442x + 60.205 
0
10
20
30
40
50
60
70
80
90
100
0 0.5 1 1.5 2
ti
m
e
 i
n
 m
in
s 
Troponin T level (ng/ml) 
SCATTER DIAGRAM FOR Total cross clamp time vs 
troponin -T 
total cramp time
Linear (total cramp time)
y = 1.5554x + 0.8905 
0
1
2
3
4
5
6
7
0 0.5 1 1.5 2
D
u
ra
ti
o
n
 o
f 
p
o
st
o
p
 s
u
p
p
o
rt
s 
in
 d
a
y
s 
Troponin-T (ng/ml) 
ScatterDiagram for Duration of postop  supports 
vs troponin - T 
Duration of postop  supports
Linear (Duration of postop
supports)
48 
 
 
 
 
 
 
 
y = 22.395x + 8.4134 
0
20
40
60
80
100
120
140
0 0.5 1 1.5 2
D
u
ra
ti
o
n
 o
f 
v
e
n
ti
la
ti
o
n
 i
n
 h
rs
 
Troponin T (ng/ml) 
scatter  diagram for Duration of ventilation vs 
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DESCRIPTIVE STATISTICS FOR THE VARIABLES 
Troponin-T level correlation Pearson correlation Significance 
 (2-tailed) 
Total 
number 
Total cross clamp time 0.394 0.004 51 
CPB duration 0.172 0.228 51 
LTOC 0.124 0.387 51 
ATOC 0.222 0.117 51 
Number of CP 0.134 0.349 51 
Postop supports 0.263 0.062 51 
Duration of postop supports 0.362 0.009 51 
Duration of ventilation 0.376 0.007 51 
Requirement of IABP -0.06 0.684 51 
ECG/ECHO evidence of ischemia 0.429 0.002 51 
Clinical evidence of cardiac failure 0.400 0.004 51 
Post op Ejection Fraction 0.605 0.001 51 
ICU stay 0.033 0.818 51 
Total hospital stay after surgery 0.142 0.319 51 
mortality 0.242 0.087 51 
 
Significant at <0.05 
From the above table,  it can be seen that the Troponin-T level has significant correlation 
with the following variables: 
1. Total cross clamp time (p value 0.004) 
2. Duration of postoperative supports (p value 0.009) 
3. Duration of ventilation (p value 0.007) 
4. ECG/ECHO evidence of ischemia (p value 0.002) 
5. Clinical evidence of cardiac failure (p value 0.004) 
6. Postoperative Ejection Fraction (p value 0.001) 
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ROC (RECEIVER – OPERATOR - CHARACTERISTIC) CURVE 
 
Post op_failure Number  
 
YES 11 
NO 40 
 
 
 
 
 
Test Result Variable(s): TroponinT 
Area 
.734 
 
 
Based on the above ROC curve for post operative complications and troponin T levels, the 
optimum cut off level for troponin T is 0.6 ng/ml (Area under the curve is 73.4%) 
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INDEPENDENT T-Test (Test of significance between two groups) 
 
 
 
 
GROUP STATISTICS 
 
 Troponin 
value N Mean 
Std. 
Deviation 
Std. Error 
Mean 
 less than 0.6 29 .4163 .12311 .02286 
above 0.6 22 1.0464 .40156 .08561 
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Levene's Test for Equality of 
Variances 
F Sig. T  
Sig. 
(2-tailed) 
95% Confidence Interval 
of the Difference 
Upper Lower 
TroponinT 32.817 .000 7.991  .00006* .78846 .47157 
*significant at 0.05 level 
 
 
ASSOCIATION BETWEEN CHARACTERISTIC VARIABLES AND 
TROPONIN T VALUE: 
S. No Variables  Troponin T (ng/ml) Total  Chi-square value P value 
< 0.6 > 0.6 
1. Total cross clamp time 
 < 70 8 19 27 4.268 0.039* 
> 70 14 10 24 
2. CPB time 
 < 90 9 0 9 8.291 0.004* 
> 90 20 22 42 
3. LTOC      
 < 25 5 0 5 4.205 0.040* 
> 25 24 22 46 
4. ATOC 
 < 25 13 7 19 0.888 0.346 
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> 25 16 15 31 
5. NO. of CP 
 < 2 17 14 31 0.132 0.716 
> 2 12 8 20 
6. Post OP support 
 Nil  6 9 15 9.009 0.011* 
Minimal/Intermediate 22 8 30 
High  1 5 6 
7. Duration of post OP support 
 < 2 days 23 14 37 0.002 0.964 
> 2 days 6 8 14 
8. Requirement of IABP 
 No  28 22 50 0.774 0.379 
Yes  1 0 1 
9. Post OP failure  
 No  25 15 40 3.659 0.056* 
Yes  4 7 11 
10. Post OP EF score 
 < 50 % 12 0 12 11.905 0.001* 
> 50 % 17 22 39 
11. Mortality  
 No  29 20 49 2.744 0.098 
Yes  0 2 2 
*. The Chi-square statistic is significant at the 0.05 level 
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From the above table, the following impressions are obtained. 
1. The duration of cross clamp time has significant positive correlation with 
Troponin-T levels (p value 0.039) 
2. The duration of CPB also has significant positive correlation with Troponin-T (p 
value 0.004) 
3. Longest Time Off Cardioplegia has significant correlation with elevation of 
Troponin-T (p value 0.040) 
4. High Troponin-T levels has significant correlation with Requirement of high 
doses of inotropes (p value 0.011) 
5. High Troponin-T levels are associated with reduced Ejection Fraction in the 
postoperative period (P value 0.001) 
 
LIMITATIONS OF THE STUDY: 
1. Total number patients studied is less. 
2. It is not a randomized controlled study. 
3. Patients were operated by different surgeons and different surgical units. 
Different surgical units may have different approach in postoperative 
management, for example, early extubation versus late extubation, inotropic 
supports initiation and weaning, etc., 
4. Two patients had trans-septal approach (through right atrium) for mitral valve 
replacement. These two patients had De Vega annuloplasty in addition to MVR. 
Their Troponin-T values were 1.390 and 1.080 ng/ml. In this surgical approach, 
an additional incision is made in the inter-atrial septum. The cause for highly 
elevated values may be due to two incisions (right atrium and septum) and may 
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also be due to excessive retraction or due to the additional procedure (De Vega 
annuloplasty). 
5. One patient had two incisions in the heart. MVR was done through left arial 
incision. Right atrium was then opened to perform De Vega annuloplasty. This 
patient’s Troponin-T was 0.566 ng/ml.  
6. One patient had prolonged hospital stay (30 days) and her Troponin-T value was 
0.871 ng/ml. But the reason for her prolonged hospital stay was due to 
sternotomy wound infection. This is a confounding factor in the variable. 
7. One patient had failed PTMC and subsequently taken up for surgery. It is not 
known whether PTMC causes elevation of Troponin-T, but MVR surgery was 
done only after 1 month. Hence, the previously attempted PTMC is unlikely to 
influence the results of Troponin-T values. Her Troponin-T value was 0.430 
ng/ml. 
8. One patient died on 5th post-operative day. Postoperative echo showed moderate 
to severe aortic regurgitation (preoperative echo showed only mild AR). This 
may be due to unmasking of AR by improved hemodynamics after MVR 
surgery. The patient’s Troponin-T value was 1.570 ng/ml. 
9. Two patients had adherent left atrial clot. They underwent clot removal and left 
atrial exclusion done by internal circumferential sutures with 4-0 prolene. The 
clot removal process or LAA exclusion procedure may be additional sources of 
Troponin-T elevation. Their Troponin-T values were 0.668 and 0.499. 
10. One patient underwent partial maze procedure for atrial fibrillation (using 
electrocautery). Her Troponin-T value was 0.517 ng/ml. 
 
 
58 
 
DISCUSSION 
Though this study was done with limited number of patients, it clearly shows that 
prolonged cross clamp time is associated with elevated Troponin-T values and that elevated 
Troponin-T values are associated (significant association) with increased morbidity in the 
form of prolonged ventilatory support, prolonged  inotropic support,  requirement of high 
doses of inotropes, postoperative cardiac failure and poor ventricular ejection fraction.  
The per-operative variables that are associated (significantly) with high levels of 
Troponin-T are 1. Prolonged cross clamp time (more than 70 minutes), 2. Prolonged CPB 
time (>90 minutes) and 3. Prolonged CP time (>25 minutes between 2 cardioplegia doses). 
By ROC curve analysis, the cut-off value of Troponin-T, was derived, above which 
the morbidity is significantly increased. The cut-off value is 0.6 ng/ml. (In a study 
conducted by Bernard l. Croal et al, with 1365 patients, and published in “Circulation” 
Journal, 2006;114:1468-1475, the cut-off value derived by ROC curve analysis, was 0.46 
ng/ml and it was proved that the mortality significantly increased above this value).14 
In this study, Troponin-T levels show good correlation with aortic cross clamp time, 
CPB duration and prolonged CP interval as well as postoperative variables like prolonged 
inotropic supports, high dose inotropes, prolonged ventilation and reduced LV function 
(poor EF). Hence, it is clear that Troponin-T is a good tool to assess the adequacy of 
myocardial protection.  
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CONCLUSION 
Troponin-T is a reliable indicator of extent of myocardial injury in cardiac surgical 
patients and is a good armamentarium in the pool of diagnostics in cardiothoracic surgical 
field. 
This test should be used more often than now, in postoperative period, to assess the 
adequacy of myocardial protection. This will have two important implications. 
1. In an individual patient, who is hemodynamically unstable in the postoperative 
period, this test is helpful, in defining the cause of  it. 
2. The efficiency of different techniques of myocardial protection may be 
compared with one another, based on Troponin-T levels. 
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